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Projects at a glance 
Main project: PS89 – Chapter 1-4 
Targeting the ER-Mitochondrial Interface of Cell Death  
Sensitizes Leukemia Cells Towards Cytostatics Combination chemotherapy has proved to be a favorable strategy to treat acute leukemias. However, the integration of novel pharmaceutical approaches remains challenging and is associated with a lack of understanding the mechanistic background of successful combination therapies. In the present study, we demonstrate a highly increased response of various acute leukemia cell lines, drug resistant cells and patient derived xenograft ȋPDXȌ cells combining cytostatics with the recently introduced protein disulfide isomerase ȋPDIȌ inhibitor PSͺͻ. In order to elucidate the source of the robust antileukemic effects, we applied activity-based protein profiling. This screening revealed a polypharmacological character of PSͺͻ targeting a network of endoplasmic reticulum ȋERȌ homeostasis proteins. In combination with cytostatics, we show that the strong apoptosis induction is orchestrated by the direct PSͺͻ target B-cell receptor-associated protein ͵ͳ ȋBAP͵ͳȌ which transduces apoptosis signals at the ER-mitochondrial interface. The activation of caspase-ͺ and cleavage of BAP͵ͳ precede a pro-apoptotic crosstalk including ER calcium and reactive oxygen species ȋROSȌ resulting in stimulation of the intrinsic apoptosis pathway. Achieving to tune these amplification loops imparts PSͺͻ the unique ability to sensitize acute leukemia cells at subtoxic concentrations. This uncovers that the ER-mitochondrial Ǯsocial network of cell deathǯ can be exploited for synergistic drug combinations.  
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Side project: Vioprolide A – Chapter 5 
Anticancer Effects and Transcriptomic Regulation 
by the Myxobacterial Compound Vioprolide A Vioprolide A ȋVioAȌ is a highly active cyclic peptide isolated from the myxobacterium 
Cystobacter violaceus and was first published in the ͳͻͻͲs. However, it seemed to fall into oblivion as no pharmaceutical studies have been published since then. Here, we point out that VioA deserves much closer attention as low nanomolar concentrations of the compound were able to induce strong apoptotic effects in Jurkat leukemia cells while peripheral bone mononuclear cells ȋPBMCsȌ of healthy donors remained unaffected. The versatility of VioA was further demonstrated by an inhibition of proliferation, colony formation as well as migration of TʹͶ bladder carcinoma cells. Moreover, the study outlines pioneer work in VioA signaling with the presentation of a transcriptome screening by massive analysis of cDNA ends ȋMACEȌ. Both the strong anticancer effects and the initial findings on the transcriptional regulation mediated by VioA finally encourage the exploitation and further development of this exceptionally potent natural compound for chemotherapy.  
  
Contribution: P8-D6 – Chapter 6 
Antileukemic effects of the dual topoisomerase inhibitor Pͺ-D͸ Interference with topoisomerases is an effective strategy for cancer therapy. At the University of Kiel, C. Meier et al recently synthesized analogs of naturally occurring benzo[c]phenanthridines revealing Pͺ-D͸ which is a powerful inducer of apoptosis. This is caused by an equipotent inhibition of topoisomerase I and II activities. In contribution to this project, we highlight the synergistic interaction of Pͺ-D͸ with PSͺͻ and its strong antileukemic effects associated with Gʹ cell cycle arrest and DNA damage in Jurkat cells.
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1 Introduction 
1.1  Acute Leukemia: Disease and Therapy 
1.1.1 Epidemiology and pathobiology Leukemia is a heterogeneous group of hematologic malignancies characterized by an uncontrolled accumulation of immature white blood cells termed blasts or leukemia cells.ͳ In contrast to chronic forms which may persist for years without major signs, acute leukemia progresses rapidly without therapeutic intervention. As functionless blasts displace the normal bone marrow cells, patients develop symptoms such as easy bleeding and fatigue caused by platelet deficiency and anemia. Furthermore, they suffer from a higher susceptibility to infections as a consequence of an inadequate white cell count.ʹ The malignant transformation can affect lymphoid and myeloid progenitor cells which defines the main types acute lymphoblastic leukemia ȋALLȌ and acute myeloid leukemia ȋAMLȌ. Both feature distinct disease characteristics and thus require specialized therapeutic management.  ALL is the most common childhood cancer.͵ Based on the US population, the median age at diagnosis is ͳͷ years. Though, the incidence among ͳ- to Ͷ-years-olds is nearly eight times higher than for young adults ʹͲ-ʹͶ years and four times higher than for elderly persons ͺͲ-ͺͶ years.Ͷ The improved survival of pediatric ALL patients is one of the success stories of cancer research with a ͷ-year survival rate increasing from ͷ͹% ȋdiagnosis ͳͻ͹ͷ-ͳͻ͹ͻȌ to ͻͲ% ȋdiagnosis ʹͲͲ͵-ʹͲͲͻȌ.͵ However, the percentage of all patients surviving ͷ years is ͸ͺ.ͳ% ȋFigure ͳaȌ which indicates that a medical need persists especially for adult and relapsed ALL patients.ͷ The initial pathogenic events leading to ALL are largely unknown, though several genetic lesions have been identified that favor an unlimited self-renewal capacity and excessive proliferation. For example, over ͷͲ% of T-cell ALLs feature activating mutations in the NOTCHͷ gene which encodes a transmembrane receptor that causes oncogenic signaling.͸ Another frequent characteristic of ALL are chromosomal translocations such as TEL-AMLͷ, which is the most frequent translocation in childhood B-cell precursor ALL and may serve as a first-hit mutation providing altered self-renewal and survival properties.͹ Though large sets 
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of data have been generated to date, the challenge persists to translate an increasing understanding of the pathobiology into effective therapies.  In a similar way, this challenge accounts for AML. The evaluation of disease-related factors such as genetic markers is an active field of research and a number of mutations have demonstrated a prognostic value. These include the NPMͷ gene, which is the most frequent mutation in AML, and FLT͹ internal tandem duplications ȋITDsȌ that activate receptor tyrosine kinase signaling.ͺ Besides, patient-associated factors including age and comorbidities are predictive for survival. The median age at diagnosis is ͸͹ years and incidence rates have increased since the early ͳͻͻͲs, a trend that will likely continue in ageing societies ȋFigure ͳb, ͵.͵ cases/ͳͲͲ.ͲͲͲ in ͳͻͻʹ vs Ͷ.͵/ͳͲͲ.ͲͲͲ in ʹͲͳ͵Ȍ. Although long-term survival has improved for younger AML patients,ͻ there has been little progress for patients aged >͸Ͳ years who represent the bulk of AML cases. Thus, todayǯs percentage of all patients surviving ͷ years remains low at ʹ͸.͸% ȋFigure ͳbȌ.  
  a             b     Figure 1│ALL and AML statistical facts based on the US population. Percentage of new cases and deaths per 
100.000 persons over time, 5-year survival of patients diagnosed 2006-2012 and median age at 
diagnosis (2009-2013). (a) ALL and (b) AML. Source: SEER Cancer Statistics Review 1975-2013.4 
1.1.2 Chemotherapy and associated challenges Five decades after the successful implementation and systematic clinical documentation of drug treatment in acute leukemia,ͳͲ combination chemotherapy has proved to be a favorable strategy in both ALL and AML. Attributed to the fast progression of the disease, immediate induction chemotherapy is essential to reduce the burden of blasts in the bone marrow <ͷ% ȋcomplete remissionȌ. Commonly, this is followed by a consolidation and / or maintenance phase in order to eradicate remaining leukemia cells and prevent relapse.ͺ, ͳͳ  
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In ALL, induction therapy utilizes an arsenal of chemotherapeutic drugs which are adjusted based on the patientǯs prognostic factors. It includes amongst others the tubulin binder vincristine ȋVCRȌ, topoisomerase inhibitors such as daunorubicin ȋDNRȌ and etoposide ȋETOȌ, corticosteroids and the alkylating agent cyclophosphamide.ͳͳ, ͳʹ In addition, patients with Philadelphia chromosome positive ALL profit from tyrosine kinase inhibitors such as imatinib.  Similarly, targeted approaches are underway for different types of AML, for example the multi-target protein kinase inhibitor midostaurin for patients with FLT͵ mutated AML. This compound is currently investigated in a phase III trial and shows to prolong survival in combination with cytarabine ȋAra-CȌ and DNR,ͳ͵, ͳͶ which have remained the primary drugs of AML induction therapy to date. Provided that an intensive chemotherapy is possible, patients commonly receive the so-called ͹+͵ regimen meaning seven days of Ara-C with three days of an anthracycline. With this strategy, complete remission is achieved in ͸Ͳ-ͺͲ% of younger adults and in ͶͲ-͸Ͳ% of >͸Ͳ year old patients.ͳͷ  However, the situation persists unsatisfactory especially for patients who relapse or are unable to receive intensive chemotherapy and therefore face very limited options.ͳͷ Besides, chemotherapy regimens of both ALL and AML are accompanied by severe side effects. This toxicity issue is further challenged by the development of leukemic cell resistances that have been demonstrated for several cytostatics including tubulin binders and topoisomerase inhibitors.ͳ͸, ͳ͹ Thus, there remains a strong need for novel pharmaceutical strategies which will be of great value if they achieve an improvement in the balance of tolerable dosing versus effective cytotoxicity in combination with current standard therapy.ͳͺ, ͳͻ 
1.2 Targeting ER Homeostasis: a Source for Novel Anticancer Drugs 
1.2.1 ER stress and unfolded protein response As accumulating evidence attributed a pro-tumorigenic role to processes within the endoplasmic reticulum ȋERȌ, it yielded increasing attention in the search for novel tumor targets.ʹͲ The ER is the central organelle for calcium storage, protein folding and 
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maturation. However, multiple stimuli and pathological conditions can alter ER function leading to an imbalance between ER protein load and folding capacity known as ER stress.ʹͳ Aiming to reduce the accumulation of unfolded proteins and restore ER homeostasis, a series of compensatory mechanisms is initiated which constitutes the unfolded protein response ȋUPRȌ.ʹʹ The master regulator of the UPR is the ER chaperone BIP which is titrated away from the luminal domains of the three sensors IREͳȽ, ATF͸Ƚ and PERK by misfolded proteins ȋFigure ʹ, leftȌ. The following signaling pathways are thoroughly summarized in Figure ʹ and commonly aim to stimulate protein folding and attenuate protein synthesis during ER stress conditions. The UPR thus exhibits a cytoprotective function which is physiologically induced as an adaptive response, though frequently activated in cancer cells.ʹ͵ However, prolonged and severe UPR activation resulting from unresolved ER stress may lead to apoptotic cell death ȋFigure ʹȌ and therefore provides an opportunity for pharmaceutical intervention.   
 Figure 2│The unfolded protein response (UPR) signaling pathways. Upon ER stress, unfolded and misfolded 
proteins bind and sequester immunoglobulin heavy-chain binding protein (BIP), thereby activating the 
UPR. The UPR comprises 3 parallel signaling branches: PRKR-like ER kinase (PERK)–eukaryotic 
translation initiation factor 2α (eIF2α), inositol-requiring protein 1α (IRE1α)–X-box binding protein 1 
(XBP1) and activating transcription factor 6α (ATF6α). The outcome of UPR activation increases 
protein folding, transport and ER-associated protein degradation (ERAD), while attenuating protein 
synthesis. If protein misfolding is not resolved, cells enter apoptosis. CHOP, C/EBP homologous 
protein; GADD34, growth arrest and DNA damage-inducible protein 34; JNK, JUN N-terminal kinase; 
P, phosphorylation; RIDD, regulated IRE1-dependent decay; ROS, reactive oxygen species; S1/2P, 
Site-1/2 protease; XBP1s, transcriptionally active XBP1; XBP1u, unspliced XBP1. Figure and legend 
adapted from M Wang and RJ Kaufman.23 
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1.2.2 ER-mitochondrial crosstalk in apoptosis signaling The switch from adaptive to fatal UPR likely depends on the intensity and duration of ER stress, though the underlying mechanisms are incompletely understood.ʹʹ, ʹ͵ However, an increasing number of studies recently indicated that the communication of ER stress and mitochondrial apoptosis has an essential role for cell fate decision.ʹͶ-ʹ͹ In this conception, bidirectional signaling loops finally result in a significant amplification and are the key to exceed the critical point of no return for apoptosis induction. Besides the pro-apoptotic transcription factor CHOP, ER calcium and mitochondrial ROS, the B-cell receptor-associated protein ͵ͳ ȋBAP͵ͳȌ has been identified as a key communicator in this so-called Ǯsocial network of cell deathǯ.ʹͷ, ʹ͹ BAP͵ͳ functions as an ER protein sorting factor in its native state,ʹͺ though has been identified to associate with the mitochondrial protein Fisͳ upon apoptotic stimuli. So, this protein complex is able to bridge the ER-mitochondrial interface and serves as a platform for caspase-ͺ ȋCASPͺȌ activation.ʹͻ Active caspase-ͺ in turn is able to cleave BAP͵ͳ into pʹͲBAP͵ͳ which promotes calcium release from the ER and apoptosis ȋFigure ͵, caspase recognition sites Dͳ͸Ͷ and Dʹ͵ͺ are outlinedȌ.͵Ͳ, ͵ͳ 
 Figure 3│Schematic representation of the B-cell receptor-associated protein 31 (BAP31). BAP31 contains three 
ER transmembrane domains and a cytosolic tail (caspase recognition sites are shown) with an ER 
retrieval sequence (KKEE). Cleavage of the cytosolic tail by caspase-8 leads to the pro-apoptotic 
p20BAP31 fragment. Figure adapted from Breckenridge et al.31 Interestingly, a recent report highlighted that BAP͵ͳ also transduces apoptotic signals from the ER to mitochondria under ER stress.͵ʹ Consistently, the critical role of the CASPͺ-BAP͵ͳ axis has been demonstrated earlier in ER stress-triggered apoptosis of B-cell lymphocytic leukemia cells.͵͵ Thus, BAP͵ͳ appears to be an important mediator of pro-apoptotic ER stress signaling which finally raises the question if currently developed ER targeting drugs could make use of this route to switch the pro-survival mode of the UPR into apoptosis.  
ER lumen BAP31
Cytosol
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1.2.3 Advances in the development of ER interfering drugs Motivated by the chance to reverse the UPR pro-survival effects as a novel pharmaceutical strategy, there has been progress in the development of ER interfering drugs in recent years.ʹͲ, ʹ͵ This was encouraged by the successful clinical application of the proteasome inhibitor bortezomib which functions as an ER stress inducer.͵Ͷ In addition, a phase I-II clinical trial lately suggested that childhood relapsed ALL patients profit from bortezomib in combination with chemotherapy.͵ͷ Another promising compound class are inhibitors of the chaperone Heat-shock protein ͻͲ ȋHspͻͲȌ that are in clinical development against several malignancies including AML and have demonstrated to be a useful co-treatment as well.͵͸, ͵͹ Finally, several anticancer approaches that directly target ER stress sensors are at preclinical stage, for example inhibitors of PRKR-like ER kinase ȋPERKȌ and inositol-requiring protein ͳȽ ȋIREͳȽȌ.ʹʹ, ͵ͺ, ͵ͻ Importantly, the key enzyme family for the maintenance of oxidative protein folding in the ER, namely protein disulfide isomerases ȋPDIsȌ, have also been recognized as druggable targets for cancer therapy. Therefore, an increasing scientific interest evolved for a novel group of substances, the PDI inhibitors. 
1.2.4 Therapeutic potential of protein disulfide isomerase inhibitors The human PDI gene family contains ʹͳ members which facilitate protein folding in the ER through the oxidation, reduction and isomerization of disulfide bonds.ͶͲ Furthermore, several PDIs including the best studied isoform ͳ ȋPDI, gene name PͺHBȌ feature chaperone activity.Ͷͳ Hence, they are key regulators of ER homeostasis.  As proliferating cancer cells face environmental stress and a global increase in protein synthesis, PDIs are frequently overexpressed and support tumor survival.ʹͲ, Ͷʹ Though a systematic analysis in leukemia is missing, individual reports have discovered overexpression of several PDI isoforms associated with chemoresistance in ALL and AML cells.Ͷ͵-Ͷͷ In addition, a novel role of PDI was identified during the UPR in leukemic cells of AML patients by suppressing myeloid differentiation.Ͷ͸ Therefore, PDIs became attractive targets in the context of solid tumors as well as hematologic malignancies.  
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In practice, the therapeutic potential of PDI targeting has been stressed with the introduction of novel inhibitors, the most promising being PACMA͵ͳ and CCF͸Ͷʹ.Ͷ͹, Ͷͺ These compounds in fact showed a strong in vitro and in vivo activity against ovarian cancer and myeloma cells, respectively. However, their irreversible mode of action is in general pharmacologically less desired and their utility in combination with standard therapy remains obscure. Interesting issues in the development of alternative PDI inhibitors therefore concerned their binding mode as well as their impact in combinatory approaches. These points were particularly respected in the development of the novel PDI inhibitor PSͺͻ and will be addressed in the following section. 
1.3 Development and Characterization of PS89 
1.3.1 Introduction of a novel compound class: the T8 family As the starting point of the present study, a compound screening for the chemosensitization towards etoposide-induced cell death revealed the lead structure Tͺ which was able to induce synergistic apoptosis in various cell lines.Ͷͻ Aiming to explore the structure-activity relationship and to increase the potency of the compound, several Tͺ-derviatives, named PSͺ͵-PSͺͻ, were prepared. Among these, PSͺͻ demonstrated the best sensitizing activity and was therefore subjected to a closer mechanistic investigation.  
1.3.2 Inhibition of protein disulfide isomerase The discovery of the Tͺ class was accompanied by a proteomic analysis of cellular targets in MDA-MB-ʹ͵ͳ breast cancer cells which revealed PDI ȋgene name PͺHBȌ as a main target protein. Further investigations demonstrated that especially PSͺͻ was able to inhibit the reductase activity of recombinant PDI ȋICͷͲ ͹ͺ ± ͳ͹ µMȌ and molecular docking studies showed that PSͺͻ binds in close proximity to the catalytic centers of PDI.Ͷͻ As illustrated in Figure Ͷ, PSͺͻ in fact shields the two active sites of PDI and their catalytically active cysteines which are responsible for the disulfide exchange reactions ȋleft: active domain aǯ, center: molecular structure of PSͺͻ, right: active domain a; cysteines are depicted by yellow dotsȌ.    
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           Figure 4│Molecular docking of PS89 and protein disulfide isomerase (PDI). Collective view of the energetically 
best 10 structural clusters of PS89 around the catalytic sites of PDI. The active domains a’ (left) and a 
(right) are shown and the catalytic cysteine residues are represented in yellow. Figure adapted from 
Eirich et al.49 
1.3.3 Significance of PS89 and open issues In contrast to most of the published PDI inhibitors, PSͺͻ unifies a number of favorable pharmacologic characteristics: first, a suitable druglikeness with satisfaction of the Lipinski rule of five. Second, a reversible mode of action which is generally beneficial in terms of drug surveillance. And finally, an exceptional chemosensitizing character shown by the combination treatment with etoposide which resulted in a highly increased apoptotic response of Jurkat cells.  These suitable properties predestined PSͺͻ not only for further combination therapy studies, but also for a deeper analysis of its interactive signaling. In particular, the last point raised the central question of the present study:     
1.4 Aims of the Study The signaling underlying the chemosensitizing effects of PSͺͻ was of special interest as there is a general agreement that combination therapies benefit from a certain form of crosstalk, but the mechanisms of interaction have only been explored for a few.ͷͲ This coincides with the persisting challenge to integrate novel drugs into acute leukemia therapy. Thus, the agenda broadly aimed to improve the understanding of combination 
 
PS89 
How does PSͺͻ cooperate with cytostatics to achieve synergistic apoptosis in leukemia cells? 
 I N T R O D U C T I O N     17 
  
therapy signaling and finally overcome the lack of response towards available cytostatics in acute leukemia.  The precise goals of the thesis can be summarized as follows: 1. Assessing the potential of PSͺͻ combination therapies in acute leukemia cell lines, drug resistant and patient-derived xenograft ȋPDXȌ cells 2. Validating the impact of protein disulfide isomerase ȋPDIȌ aȌ as a single target and bȌ in relationship to further PSͺͻ target proteins from a network perspective 3. Investigating the pro-apoptotic function of the novel PSͺͻ target protein B-cell receptor-associated protein ͵ͳ ȋBAP͵ͳȌ 4. Elucidating the interactive apoptosis signaling between PSͺͻ and cytostatics  
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2 Materials and Methods 
2.1 Materials 
2.1.1 Cells 
2.1.1.1 Cell lines 
Table 1│List of cell lines A verification of Jurkat wildtype cells was performed prior to start of the project at the German Collection of Microorganisms and Cell Cultures ȋDSMZȌ. Generation and characteristics of genetically modified Jurkat cells has been described previously.ͷͳ, ͷʹ Acquirement and profile of vincristine resistance in CEM cells ȋVCR-R CEMȌ has been characterized by the group of M. Kavallaris.ͷ͵-ͷͷ 
2.1.1.2  Patient derived xenograft cells The model of acute leukemia patientsǯ cells growing in mice has been described previously.ͷ͸, ͷ͹ Patient derived xenograft ȋPDXȌ cells were kindly provided by the group of Prof. Dr. Irmela Jeremias ȋHelmholtz Center, Munich, GermanyȌ after isolation from the bone marrow or spleen of NSG mice. Characteristics of PDX cells used in the present study are summarized in Table ʹ.     
Cell line Supplier or academic partner CCRF-CEM M. Kavallaris, Sydney, Australia HEK ʹͻ͵ DSMZ, Braunschweig, Germany Hela DSMZ, Braunschweig, Germany HL-͸Ͳ ATCC, Manassas, VA, USA Jurkat WT P. H. Krammer, Heidelberg, Germany Jurkat/neo P. H. Krammer, Heidelberg, Germany Jurkat/Bcl-͸ P. H. Krammer, Heidelberg, Germany Jurkat/Bcl-xL P. H. Krammer, Heidelberg, Germany Jurkat CASPͺ -/- P. H. Krammer, Heidelberg, Germany VCR-R CEM M. Kavallaris, Sydney, Australia 
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 Table 2│Samples and characteristics of patient derived xenograft (PDX) cells. ALL: Acute lymphoblastic 
leukemia, AML: Acute myeloid leukemia. Subtype classification ALL: according to type of lymphoblast 
(B cell or T cell) and immunophenotype. AML: according to type of myeloblast based on the French-
American-British (FAB) system. n/a: not available. 
2.1.1.3  Peripheral blood mononuclear cells Peripheral blood mononuclear cells ȋPBMCsȌ were freshly isolated from blood of healthy donors by gradient centrifugation as described in section ʹ.͵. 
2.1.2 Compounds The study compound PSͺͻ as well as the PSͺͻ photo probe ȋJPͲͶ-ͲͶʹȌ were synthesized and provided by Prof. Dr. Uli Kazmaier ȋSaarland University, Saarbru cken, GermanyȌ. The structures are shown in Figure ͷ and chemical properties of the compound family have been characterized.Ͷͻ 
           a      b  
         Figure 5│Chemical structures of study compounds. (a) PS89 and (b) the PS89 photo probe (JP04-042) 
modified by an alkyne handle. The cytostatics etoposide ȋETOȌ, daunorubicin ȋDNRȌ and vincristine ȋVCRȌ were obtained from Sigma Aldrich ȋSt Louis, MO, USAȌ. Cytarabine ȋAra-CȌ was purchased from Merck ȋDarmstadt, GermanyȌ.   
2.1.3 Antibodies 
Sample Type Subtype Disease Stage Sex Age ALL-ͳ͸ͺ ALL  Pre-B ALL Initial diagnosis Female ͷ ALL-ʹ͵Ͳ ALL T ALL Initial diagnosis Male Ͷ AML-346 AML M7 Relapse Female 1 AML-372 AML M0 Relapse Male 42 AML-393 AML M4 Relapse Female 47 AML-491 AML n/a Relapse Female 53 
Primary antibody Origin Supplier Actin Clone CͶ Mouse Millipore, Darmstadt, Germany Alexa Fluor Ͷͺͺ IgGʹb κ Isotype Control  Mouse BD, Franklin Lakes, NJ, USA  BAP͵ͳ C-ͳͷ Goat Santa Cruz, Dallas, TX, USA 
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Table 3│List of primary antibodies 
Table 4│List of secondary antibodies 
2.1.4 Small interfering RNAs For gene silencing, ON-TARGETplus SMARTpool small interfering RNA ȋsiRNAȌ reagents from GE Dharmacon ȋLafayette, CO, USAȌ against human PDI ȋgene name PͺHBȌ and BAP͵ͳ ȋgene name BCAP͹ͷȌ were used. ON-TARGETplus non-targeting control siRNA, designated as siCtrl, served as control to determine baseline cellular responses in RNA interference experiments. siRNAs were resuspended according to Dharmacon instructions in ͳx siRNA buffer ȋdiluted from Dharmacon ͷx siRNA buffer in RNase-free waterȌ to a stock concentration of ʹͲ µM and stored at -ʹͲ°C. 
2.1.5 Plasmid encoding protein disulfide isomerase Overexpression of PDI ȋgene name PͺHBȌ was performed using pPDI vector kindly provided by W. Ou ȋBethesda, MD, USAȌ.ͷͺ The non-coding plasmid pcDNA͵.ͳ ȋThermo Fisher, Waltham, MA, USAȌ served as empty vector control.  
BAP͵ͳ B-ͳͲ Mouse Santa Cruz, Dallas, TX, USA BAP͵ͳ HPAͲͲ͵ͻͲ͸ Rabbit Sigma Aldrich, St Louis, MO, USA Bcl-ʹ #ʹͺ͹ʹ Rabbit Cell Signaling, Danvers, MA, USA Bcl-xL #ʹ͹͸ʹ Rabbit Cell Signaling, Danvers, MA, USA Caspase-3, Active C8487 Rabbit Sigma Aldrich, St Louis, MO, USA Caspase-8 1C12 Mouse Cell Signaling, Danvers, MA, USA Cytochrome c #4272 Rabbit Cell Signaling, Danvers, MA, USA PARP #9542 Rabbit Cell Signaling, Danvers, MA, USA PE  IgGʹb κ Isotype Control Mouse BD, Franklin Lakes, NJ, USA PDI C81H6 Rabbit Cell Signaling, Danvers, MA, USA VDAC #4866 Rabbit Cell Signaling, Danvers, MA, USA 
Secondary antibody Origin Supplier Anti-goat IgG, HRP ͹Ͳͷ-Ͳ͵ͷ-ͳͶ͹ Donkey Dianova, Hamburg, Germany 
Anti-mouse IgG, HRP 7076 Goat Cell Signaling, Danvers, MA, USA 
Anti-mouse IgG, IRDye 800CW Goat Li-Cor, Lincoln, NE, USA Anti-rabbit Alexa Ͷͺͺ AͳͳͲͲͺ Goat Thermo Fisher, Waltham, MA, USA Anti-rabbit IgG, HRP 172-1019 Goat Bio-Rad, Hercules, CA, USA 
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2.1.6 Chemicals and reagents 
Reagent Supplier ʹ,ʹ,ʹ-Trichloroethanol ȋTCEȌ Sigma Aldrich, St Louis, MO, USA ͷ-TAMRA-Azide Jena Bioscience, Jena, Germany µMACS Protein G MicroBeads Kit Miltenyi Biotech, Bergisch Gladbach, Germany Ammonium persulfate ȋAPSȌ Sigma Aldrich, St Louis, MO, USA BCA, Uptima BC Assay Kit Interchim, Montlucon, France Bovine serum albumin ȋBSAȌ Sigma Aldrich, St Louis, MO, USA Cal-ͷʹͲ, AM AAT Bioquest, Sunnyvale, CA, USA Carboxy-HʹDCFDA Thermo Fisher, Waltham, MA, USA Cell-Titer Blue ȋCTBȌ Promega, Madison, WI, USA CompBeads Anti-mouse Ig, κ BD, Franklin Lakes, NJ, USA Complete Roche Diagnostics, Basel, Switzerland Coumaric acid Fluka, Buchs, Switzerland DMEM cell culture medium PAN Biotech, Aidenbach, Germany DMSO AppliChem, Darmstadt, Germany Fetal calf serum ȋFCSȌ PAA Laboratories, Pasching, Austria  Ficoll-Paque PLUS GE Healthcare, Chicago, IL, USA FluorSave Reagent Merck, Darmstadt, Germany Formaldehyde ͳ͸%, ultrapure Polysciences, Warrington, PA, USA FuGene HD Promega, Fitchburg, WI, USA GenaxxoFect Genaxxon, Ulm, Germany Glycerol AppliChem, Darmstadt, Germany Glycine AppliChem, Darmstadt, Germany Hoechst ͵͵͵Ͷʹ Sigma Aldrich, St Louis, MO, USA IMDM cell culture medium Thermo Fisher Gibco, Waltham, MA, USA JC-ͳ Enzo, Farmingdale, NY, USA Luminol AppliChem, Darmstadt, Germany Methylcellulose Sigma Aldrich, St Louis, MO, USA MTT Sigma Aldrich, St Louis, MO, USA NaʹEDTA x ʹ HʹO Sigma Aldrich, St Louis, MO, USA Naʹ-Ⱦ-glycerophosphate x ͷ HʹO Merck, Darmstadt, Germany Na͵VOͶ ICN Biomedicals, Aurora, OH, USA NaͶPʹO͹ x ͳͲ HʹO Sigma Aldrich, St Louis, MO, USA NaF Merck, Darmstadt, Germany Nonfat powdered milk ȋBlottoȌ Carl Roth, Karlsruhe, Germany 
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Table 5│List of dyes, inhibitors, kits and chemicals All commonly used acids, bases, buffer salts and organic solvents were either purchased from Merck ȋDarmstadt, GermanyȌ or Sigma-Aldrich ȋSt Louis, MO, USAȌ. 
2.1.7 Technical equipment 
PageRuler protein ladder Thermo Fisher, Waltham, MA, USA Penicillin-Streptomycin PAN Biotech, Aidenbach, Germany PMSF Sigma Aldrich, St Louis, MO, USA Rotiphorese Gel ͵Ͳ Carl Roth, Karlsruhe, Germany Propidium iodide Sigma Aldrich, St Louis, MO, USA Pyronin Y Sigma Aldrich, St Louis, MO, USA Pyruvate Merck, Darmstadt, Germany Q-VD-OPh Merck Millipore, Darmstadt, Germany  RPMI ͳ͸ͶͲ cell culture medium PAN Biotech, Aidenbach, Germany siRNA buffer ȋͷxȌ GE Dharmacon, Lafayette, CO, USA Sodium dodecyl sulfate ȋSDSȌ AppliChem, Darmstadt, Germany TEMED VWR, Radnor, PA, USA Triton X-ͳͲͲ Merck, Darmstadt, Germany Trypsin PAN Biotech, Aidenbach, Germany Tween ʹͲ VWR, Radnor, PA, USA YO-PRO-ͳ Thermo Fisher, Waltham, MA, USA Z-IETD-FMK R&D Systems, Minneapolis, MN, USA 
Device Function Manufacturer µMACS separator with µColumns Immunoprecipitation  Miltenyi Biotech, Bergisch Gladbach, Germany Amersham NC/PVDF ȋͲ.ʹ µM, Ͳ.Ͷͷ µMȌ Blotting membrane  GE Healthcare, Chicago, IL, USA  ChemiDoc Touch Immunoblot Imaging Bio-Rad, Hercules, CA, USA Cell culture flasks, tubes and plates Disposable cell culture material Nunc, Thermo Fisher, Waltham, MA, USA Consort power supply Eͺ͵ͷ Electrophoresis  Sigma Aldrich, St Louis, MO, USA  Curix ͸Ͳ with Super RX films Film processor with  X-ray films Agfa, Cologne, Germany Fujifilm, Tokio, Japan FACSCanto II Flow cytometer BD, Franklin Lakes, NJ, USA HBT ͳ͵Ͳ-ʹ  Thermoblock  Haep Labor Consult, Bovenden, Germany HeraCell Incubator Heraeus, Hanau, Germany ibiTreat µ-slide Microscopy ͺ-well slide Ibidi, Planegg, Germany 
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Table 6│Materials and devices for cell culture and analytics 
2.1.8 Software 
Table 7│Software tools for data interpretation 
2.2 Cell Culture 
2.2.1  Maintenance of cells CEM cells were maintained in RPMI ͳ͸ͶͲ medium with ʹ mM glutamine supplemented with ͳͲ% ȋv/vȌ heat-inactivated fetal calf serum ȋFCSȌ and a combination of ͳͲͲ U/ml penicillin and ͳͲͲ µg/ml streptomycin ȋPen/StrepȌ. Jurkat cells were cultivated in the same medium with additional ͳ mM pyruvate. Jurkat medium with ʹͲ% FCS instead of ͳͲ% FCS was used to cultivate PBMCs and ALL PDX cells. AML PDX cells were maintained in DD medium ȋStemPro-͵Ͷ SFM medium with nutrient supplement, Pen/Strep, L-glutamine, ʹ% ȋv/vȌ FCS, ͳͲ ng/mL FLT͵L, ͳͲ ng/mL SCF, ͳͲ ng/mL TPO, ͳͲ ng/mL IL͵Ȍ which was kindly provided by Prof. Dr. Irmela Jeremias ȋHelmholtz Center, Munich, GermanyȌ. HL-͸Ͳ cells were cultured in IMDM medium supplemented 
LUͳͲͷM camera Digital camera Lumenera, Ottawa, Canada Mikro ʹʹR Microcentrifuge Hettich, Tuttlingen, Germany Mini Protean ͵ Electrophoretic transfer Bio-Rad, Hercules, CA, USA Odyssey ʹ.ͳ  Western blot fluorescence imaging Licor, Lincoln, NE, USA  Olympus CK͵Ͳ Inverted microscope Olympus, Tokyo, Japan Rotina Ͷ͸R Centrifuge Hettich, Tuttlingen, Germany Tecan Sunrise Absorbance reader Tecan, Ma nnedorf, Switzerland SPͺ LSM system Confocal microscope Leica, Wetzlar, Germany SpectraFluor Plus Fluorescence reader Tecan, Ma nnedorf, Switzerland ViCell XR Cell viability analyzer Beckman Coulter, Brea, CA, USA 
Software name and version Supplier FlowJo v͹.͸.ͷ Tree Star, Ashland, OR, USA GraphPad Prism ͹ GraphPad Software, San Diego, CA, USA Image Lab vͷ.ʹ Bio-Rad, Hercules, CA, USA Leica LAS X Leica, Wetzlar, Germany LuCam Capture v͸.͵.ʹ Lumenera, Ottawa, Canada Microsoft Office ʹͲͳͲ Microsoft, Redmont, WA, USA STRING vͳͲ STRING Consortium, Zurich, Switzerland 
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with ʹͲ% FCS and Pen/Strep. HEKʹͻ͵ and Hela cells were maintained in DMEM medium ȋʹ mM glutamine, Ͷ.ͷ g/l glucoseȌ supplemented with ͳͲ% FCS and Pen/Strep.  Cells were cultivated in a humidified incubator at ͵͹°C under a ͷ% COʹ atmosphere and typically passaged three times per week. Suspension cell lines were maintained at a cell density between Ͳ.ͳ-ͳ.Ͳ x ͳͲ͸ cells/ml. Adherent cells were cultured as monolayers and passaged the latest by reaching ͺͲ-ͻͲ% of confluence. Therefore, cells were rinsed twice with PBS and detached by trypsin/EDTA ȋTable ͺȌ. The enzymatic reaction was stopped by addition of complete growth medium. For all cell lines, the cell density was determined using the cell viability analyzer ViCell XR prior to seeding for experiments or further cultivation.      Table 8│Buffers commonly applied in cell culture 
2.2.2 Stimulation with test compounds Suspension cells were seeded, unless otherwise stated, at Ͳ.ʹ x ͳͲ͸ cells/ml and stimulated after Ͷ h incubation. HEK and Hela cells were allowed to adhere and therefore typically seeded the day before treatment. DMSO stock solutions of test compounds ȋPSͺͻ, cytostatics and inhibitorsȌ were appropriately pre-diluted in growth medium, so the DMSO concentration did not exceed Ͳ.ͷ% ȋv/vȌ in all experiments.  
2.2.3 Plasmid and siRNA transfection For overexpression of PDI, Ͳ.ʹ x ͳͲ͸ HEK cells were seeded per ͸-well the day before transfection. The transfection complex was prepared according to manufacturerǯs instructions and contained ʹ µg DNA ȋpPDI or empty vector pcDNA͵.ͳȌ and ͸ µl FuGene HD reagent per well.  For gene silencing, cells were transfected using the GenaxxoFect One-Step protocol. Representative for one ͳʹ-well, ʹ µl GenaxxoFect and ͳ.ʹͷ µl siRNA ȋc = ʹͲ µMȌ were each diluted in ͺͲ µl of the supplied Dilution Buffer, mixed by rapid pipette action and 
PBS ȋpH ͹.ͶȌ  NaCl ͳʹ͵.ʹ mM NaʹHPOͶ ͳͲ.Ͷ mM KHʹPOͶ ͵.ʹ mM HʹO  
Trypsin/EDTA   Trypsin Ͳ.Ͳͷ% ȋw/vȌ NaʹEDTA Ͳ.Ͳʹ% ȋw/vȌ PBS  
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incubated for ʹͲ-͵Ͳ min at RT. Cells were freshly detached ȋif applicableȌ and resuspended in antibiotic free medium ȋͲ.ͳͷ x ͳͲ͸ cells / mlȌ, mixed gently with the transfection complexes ȋfinal V = ͳ mlȌ and transferred to the culture plate. The siRNAs used for transfection experiments are listed in section ʹ.ͳ.Ͷ. 
2.2.4 Freezing and thawing of cells For long-term storage, the cell density was adjusted to ʹ x ͳͲ͸ cells/ml in growth medium supplemented with ʹͲ% FCS, Pen/Strep and ͳͲ% DMSO. Aliquots ȋV = ͳ.ͷ mlȌ were prepared in cryo vials and immediately frozen at -ʹͲ°C for ʹͶ h, temporary stored at -ͺͲ°C and finally transferred to liquid nitrogen for long-term storage. For recultivation, frozen cells were thawed in a water bath at ͵͹°C, transferred to ʹͲ ml of growth medium and centrifuged. The DMSO-rich supernatant was discarded and the cell pellet resuspended in culture medium. Cells were subsequently expanded in a ʹͷ cmʹ flask.  
2.3 Isolation of Peripheral Blood Mononuclear Cells Peripheral blood mononuclear cells ȋPBMCsȌ were isolated from EDTA-anticoagulated blood of healthy donors ȋfinal concentration NaʹEDTA x ʹ HʹO ͳ.ͷ mg/ml bloodȌ by gradient centrifugation using Ficoll-Paque PLUS according to manufacturer's instructions. Blood was mixed ͳ:ͳ ȋv/vȌ with balanced salt solution ȋBSS, Table ͻȌ, layered on top of the Ficoll reagent and centrifuged ȋͶͷ min, ͶͲͲ g, RTȌ. Cells were collected from the PBMC layer ȋFigure ͸, light grey layerȌ and washed with BSS ȋͳͲ min, ͳͲͲ g, RTȌ to remove platelets. Cells were finally resuspended in growth medium, seeded and stimulated as previously described ȋsections ʹ.ʹ.ͳ and ʹ.ʹ.ʹȌ.          Figure 6│Cell layers after Ficoll gradient centrifugation  
BSS ȋpH ͹.͸Ȍ  NaCl ͳʹ͸ mM CaClʹ x ʹ HʹͲ Ͳ.ͲͲͷ mM MgClʹ x ͸ HʹͲ Ͳ.Ͳͻͺ mM KCl Ͳ.ͷͶ mM Tris base ͳͶ.ͷ mM D-glucose Ͳ.Ͳͳ% ȋw/vȌ HʹO  
Plasma
Lymphocytes, 
Platelets, Monocytes
Ficoll Reagent
Granulozytes
Erythrozytes Table 9│Balanced salt solution (BSS) 
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2.4 Flow Cytometry 
2.4.1 Apoptosis and cell cycle analysis Apoptosis was determined by propidium iodide ȋPIȌ staining and flow cytometry according to Nicoletti et al.ͷͻ, ͸Ͳ Therefore, cells were detached ȋif applicableȌ, washed with ice cold PBS, permeabilized and stained with fluorochrome solution ȋTable ͳͲȌ. After ͵Ͳ min incubation at Ͷ°C in the dark, cells were analyzed on a BD FACSCanto II. ͳͲ.ͲͲͲ events were measured per sample at Ex Ͷͺͺ nm and Em ͷͺͷ/Ͷʹ nm. Cell cycle analysis and percentage of apoptotic cells, represented by the subGͳ population featuring fragmented or loss of DNA, were determined with FlowJo software.      Table 10│Fluorochrome solution Exceptionally, apoptosis of daunorubicin treated HL-͸Ͳ cells was determined by YO-PRO-ͳ nucleic acid stain which selectively passes through the plasma membranes of apoptotic cells. Cells were washed with PBS, stained with YO-PRO-ͳ solution ȋc = ͳ µM in PBSȌ and directly analyzed on a BD FACSCanto II ȋEx Ͷͺͺ nM, Em ͷ͵Ͳ/͵Ͳ nmȌ. Apoptotic cells featured high YO-PRO-ͳ fluorescence and were quantified with FlowJo software. 
2.4.2 Cell death of PDX cells and PBMCs PDX cells and PBMCs were harvested after Ͷͺ h or ͹ʹ h stimulation, washed with PBS ȋRTȌ and finally resuspended in ʹͷͲ µl PBS. Cells were immediately analyzed on a FACSCanto II and the percentage of viable or apoptotic cells, respectively, was determined by forward/side scatter ȋFSC/SSCȌ gating as described.͸ͳ Exemplarily, FSC/SSC dot plots of control versus daunorubicin treated AML-͵͹ʹ PDX cells and PBMCs are shown in Figure ͹. Specific apoptosis of gate B populations, as depicted in Figure ͹, was calculated according to the following formula: 
[%]%100
[%][%]
[%]
DMSOBGate
DMSOBGateTreatedBGate
apoptosisSpecific 
  
Fluorochrome solution Propidium iodide ͷͲ µg/ml Sodium citrate Ͳ.ͳ% ȋw/vȌ Triton X-ͳͲͲ Ͳ.ͳ% ȋv/vȌ PBS  
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      AML-372          PBMCs 
              DMSO              Daunorubicin      DMSO             Daunorubicin 
            Figure 7│Determination of viable and apoptotic cells in PDX and PBMC samples. Representative FSC/SSC dot 
plots of AML-372 and PBMC samples treated with daunorubicin versus DMSO control. Gate A: viable 
myeloblasts (AML-372) or lymphocytes (PBMCs), Gate B: apoptotic cells, Gate C: debris. 
2.4.3 Cytosolic calcium Cytosolic calcium levels were determined by loading the stimulated cell suspension with the calcium indicator Cal-ͷʹͲ AM.͸ʹ Cells were incubated with ͳ µM Cal-ͷʹͲ AM for ͻͲ min at ͵͹°C and ͵Ͳ min at RT, then centrifuged ȋͷ min, ͶͲͲ g, RTȌ, washed with Hanks and Hepes Buffer ȋHHBS, Table ͳͳȌ to remove excess dye and resuspended in HHBS. The fluorescence intensity was analyzed on a FACSCanto II at Ex Ͷͺͺ nm and Em ͷ͵Ͳ/͵Ͳ nm. For quantification, debris was excluded and intracellular calcium levels were determined as the FITC-A median normalized to DMSO control.  
Table 11│Hanks and Hepes Buffer (HHBS) 
2.4.4 Mitochondrial membrane potential The mitochondrial membrane potential ȋΔΨmȌ was measured by JC-ͳ staining. The dye aggregates in the electronegative interior of mitochondria emitting red fluorescence in healthy cells. Upon dissipation of ΔΨm, the dye remains monomeric in the cytosol and shows green fluorescence.͸͵ Stimulated cells were stained with ͳ µg/ml JC-ͳ for ͵Ͳ min at ͵͹°C, washed with PBS to remove excess dye and resuspended in PBS. In parallel, compensation samples were prepared according to manufacturerǯs instructions using 
HHBS ȋpH ͹.ʹȌ   CaClʹ ͳ.ʹ͸ mM MgClʹ x ͸ HʹO  Ͳ.Ͷͻ mM D-glucose ͷ.ͷ͸ mM MgSOͶ x ͹ HʹO Ͳ.Ͷͳ mM Hepes ʹͲ mM NaʹHPOͶ Ͳ.͵Ͷ mM KCl ͷ.͵͵ mM NaCl ͳ͵͹.ͻ mM KHʹPOͶ Ͳ.ͶͶ mM NaHCO͵ Ͷ.ͳ͹ mM HʹO    
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the BD CompBeads Anti-mouse Ig, κ particles set and BD Alexa Fluor Ͷͺͺ and PE-conjugated antibodies ȋsee section ʹ.ͳ.͵Ȍ. Operating on a FACSCanto II, compensation of spectral overlap was performed prior to analysis of JC-ͳ stained cells ȋsettings Alexa Ͷͺͺ: Ex Ͷͺͺ nm, Em ͷ͵Ͳ/͵Ͳ nm; PE: Ex Ͷͺͺ nm, Em ͷͺͷ/Ͷʹ nmȌ. Debris was excluded and populations exposing green and red fluorescence were determined with FlowJo software plotting Alexa Ͷͺͺ against PE fluorescence intensity.   
2.4.5  Reactive oxygen species Reactive oxygen species ȋROSȌ were detected using the redox-sensitive probe Carboxy-HʹDCFDA. Upon cleavage of the acetate groups by intracellular esterases and oxidation by the activity of ROS, the non-fluorescent precursor is converted to the highly fluorescent ʹ´-͹´-dichlorofluorescein ȋDCFȌ.͸Ͷ Stimulated cells were harvested, washed with PBS and loaded with Carboxy-HʹDCFDA ȋʹͲ µM in PBS, incubation Ͷͷ min at ͵͹°CȌ. Cells were washed once again to remove excess dye and resuspended in PBS. The fluorescence intensity was immediately analyzed on a FACSCanto II at Ex Ͷͺͺ nm and Em ͷ͵Ͳ/͵Ͳ nm. For quantification, debris was excluded and intracellular ROS levels were determined as the FITC-A median relative to DMSO control. 
2.5  Proliferation Assay To analyze the proliferative capacity, ͷ.ͲͲͲ cells were seeded per well into ͻ͸-well plates and stimulated for ͹ʹ h with subtoxic concentrations of test compounds. Subsequently, CellTiter-Blue ȋCTBȌ reagent was added to each well at a volume ratio of ʹ:ͷ ȋv/vȌ and incubated for Ͷ h at ͵͹°C. Viable cells reduced the CTB dye resazurin into resorufin, which is highly fluorescent. With an excitation at ͷͷͲ nm, resorufin fluorescence was recorded at ͷͻͷ nm using a Tecan SpectraFluor Plus microplate reader. As a reference, the cell number on day Ͳ was determined incubating three wells with CTB at the time of stimulation ȋEm Ctrl Ͳ hȌ. Proliferation of cells was calculated relative to DMSO control according to the following formula: 
100
)0()72(
)0()72(
[%] 

hCtrlEmhDMSOEm
hCtrlEmhTreatedEmionProliferat  
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2.6 Colony Formation Assay In order to assess the ability of single cells to form colonies after short-term stimulation, Jurkat or VCR-R CEM cells at a density of Ͳ.Ͷ x ͳͲ͸ cells/ml were treated for Ͷ h with test compounds. Cells were harvested, washed with PBS to remove stimulants and resuspended in growth medium. The cell density was determined with the cell viability analyzer ViCell XR and adjusted to Ͳ.Ͳ͸ͷ x ͳͲ͸ cells/ml. Aliquots of the cell suspension ȋV = ͷͲͲ µlȌ were diluted with ͸ ml of RPMI medium supplemented with Ͳ.ͷʹ% methylcellulose ȋMCȌ and ͶͲ% FCS to promote colony growth ȋfinal concentrations: ͷ.Ͳ x ͳͲ͵ cells/ml in Ͳ.Ͷ% MC mediumȌ. This suspension was seeded in triplicates ȋV = ʹ ml per well in ͸-well platesȌ and cells were allowed to grow into colonies for ͷ d ȋVCR-R CEM cellsȌ or ͹ d ȋJurkat cellsȌ. Colonies were subsequently incubated with the yellow tetrazolium dye MTT which is reduced to purple formazan in living cells.͸ͷ Images of each well were recorded using a LUͳͲͷM camera and LuCam software from Luminera. The number of colonies per well were determined with ImageJ software by cutting the area of interest, sharpening the colored pixels, adjusting threshold to subtract background grey levels and analyzing the number of particles. The count of colony forming units ȋCFUȌ was normalized to DMSO controls. 
2.7  Immunoblotting 
2.7.1  Cell lysis and cytosolic-mitochondrial fractionation Analysis of cellular protein levels was performed by Western blot. Therefore, samples were harvested, washed once with ice-cold PBS and lyzed. For the preparation of whole cell lysates, cells were resuspended in phospho lysis buffer ȋTable ͳʹȌ, frozen at -ʹͲ°C overnight and incubated for at least ͵Ͳ min on ice. After centrifugation ȋͳͲ min, ͳͲ.ͲͲͲ g, Ͷ°CȌ, one part of the supernatants was used for protein quantification and the remaining cell lysates were stored at -ʹͲ°C if not immediately processed further.        
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Table 12│Phospho lysis buffer for the preparation of whole cell lysates For cytosolic-mitochondrial fractionation, cells were incubated with digitonin lysis buffer ȋTable ͳ͵Ȍ for ʹͲ min on ice and centrifuged ȋͳͲ min, ͳ͹Ͳ g, Ͷ°CȌ. The supernatant was collected ȋcytosolic fractionȌ and the cell pellet was permeabilized with Triton X-ͳͲͲ lysis buffer ȋͲ.ͳ% Triton-X ͳͲͲ in PBSȌ for ͳͷ min on ice ȋmitochondrial fractionȌ. Both fractions were once more centrifuged ȋͳͲ min, ͳͲ.ͲͲͲ g, Ͷ°CȌ to remove residual cell debris and further processes as whole cell lysates.  
Table 13│Digitonin lysis buffer for the separation of cytosolic from mitochondrial fractions 
2.7.2  Protein quantification and sample preparation In order to assure equal protein load, the bicinchoninic acid ȋBCAȌ assay was performed.͸͸ Therefore, ͳͲ µl of cell lysates previously diluted ͳ:ͷ ȋv/vȌ in water or bovine serum albumin ȋBSAȌ standards ȋc = Ͳ.ͳʹͷ - ʹ.Ͳ mg/mlȌ were transferred to a ͻ͸-well plate in triplicates. Samples were incubated with ͳͻͲ µl of BCA solution ȋUptima, InterchimȌ for ͵Ͳ min at ͵͹°C in the dark. The reduction of Cuʹ+ to Cu+ leading to BCA chelate formation and a purple-colored product is proportional to the amount of protein. The absorbance was measured at ͷͷͲ nm using a Tecan Sunrise reader and protein concentrations were determined by linear regression. Western blot samples were prepared mixing a lysate volume corresponding to ͵Ͳ µg protein with ͳ/ͷ ȋv/vȌ of ͷx SDS sample buffer ȋTable ͳͶȌ and with ͳx SDS sample buffer to a total volume of ͶͲ µl. Prior to gel loading, samples were boiled for ͷ min at ͻͷ°C. 
Phospho lysis buffer ȋpH ͹.ͷȌ   NaCl ͳ͵͹ mM NaͶPʹO͹ x ͳͲ HʹO ʹ mM Tris base ʹͲ mM Glycerol ͳͲ % ȋv/vȌ NaʹEDTA ʹ mM Na͵VOͶ ʹ mM Triton-X ͳͲͲ ͳ % ȋv/vȌ PMSF ͳ mM Naʹ-Ⱦ-Glycerophosphate x ͷ HʹͲ ʹͲ mM Complete ʹͷx Ͷ % ȋv/vȌ NaF  ͳͲ mM HʹO  
Digitonin lysis buffer ȋpH ͹.ʹȌ   Hepes ȋpH ͹.ʹȌ ͳͲ mM NaʹEGTA Ͳ.ʹ mM Mannitol ʹͳͲ mM Succinate ͷ mM Sucrose ʹͲͲ mM BSA Ͳ.ͳͷ % ȋw/vȌ Digitonin ͺͲ µg/ml HʹO  
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  Table 14 │SDS buffers for Western blot sample preparation 
2.7.3  Electrophoresis and blotting For protein separation, discontinuous SDS-polyacrylamide gel electrophoresis ȋSDS-PAGEȌ was performed using Polyacrylamide ȋPAAȌ gels prepared as listed in Table ͳͷ. The PAA concentration was typically ͳʹ%, though adjusted to optimal separation conditions depending on the molecular weight of the protein of interest.  The chamber of a Mini Protean ͵ system from Bio-Rad was supplied with electrophoresis buffer ȋTable ͳͷȌ and gels were loaded with samples or ʹ µl of Page Ruler Prestained protein ladder. Electrophoresis was performed for ʹͳ min at ͳͲͲ V and Ͷͷ min at ʹͲͲ V for protein stacking and separation, respectively.     
 
 
 
 
   
Table 15│Gels and buffer for SDS-PAGE Prior to blotting, equal protein load was determined by stainfree detection of trichloroethanol ȋTCEȌ supplemented gels͸͹ using a ChemiDoc Touch Imaging System. In order to make proteins accessible for immunological detection, tank electroblotting onto 
ͷx SDS sample buffer Tris-HCl ȋpH ͸.ͺȌ ͵.ͳʹͷ M Glycerol ͷͲ% ȋv/vȌ SDS ͷ% ȋw/vȌ DTT ʹ% ȋw/vȌ Pyronin Y Ͳ.Ͳʹͷ% ȋw/vȌ  HʹO  
ͳx SDS sample buffer ͷx SDS sample buffer ʹͲ% ȋv/vȌ HʹO  
Stacking Gel Rotiphorese Gel ͵Ͳ  ͳ͹% ȋv/vȌ Tris-HCl ȋpH ͸.ͺȌ ͳʹͷ mM SDS Ͳ.ͳ% ȋw/vȌ  TEMED Ͳ.ʹ% ȋv/vȌ APS Ͳ.ͳ% ȋw/vȌ HʹO  
Separation Gel ͳʹ% Rotiphorese Gel ͵Ͳ  ͶͲ% ȋv/vȌ Tris-HCl ȋpH ͺ.ͺȌ ͵͹ͷ mM SDS Ͳ.ͳ% ȋw/vȌ TEMED Ͳ.ͳ% ȋv/vȌ APS Ͳ.Ͳͷ% ȋw/vȌ TCE Ͳ.ͷ% ȋv/vȌ HʹO  
Electrophoresis buffer   Tris Ͷ.ͻ mM SDS Ͳ.ͳ% ȋw/vȌ Glycine ͵ͺ mM HʹO  
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Amersham NC or PVCF membranes ȋGE Healthcare, Ͳ.ʹ µM or Ͳ.Ͷͷ µM pore sizeȌ was performed for ͳ.ͷ h at ͳͲͲ V and Ͷ°C. The blot was run in cold ͳx tank buffer listed in Table ͳ͸.   
  Table 16 │Tank buffers for electroblotting 
2.7.4  Protein detection To prevent non-specific binding of antibodies, membranes were blocked for at least ͳ h at RT with a ͷ% ȋw/vȌ solution of milk powder in TBS-T buffer ȋTable ͳ͹Ȍ. Membranes were subsequently incubated with primary antibodies overnight at Ͷ°C. After three washing steps with TBS-T, membranes were incubated with a suitable secondary antibody for ͳ h at RT and washed again three times with TBS-T. Depending on the secondary antibody labeling, ȋAȌ enhanced chemiluminescence ȋECLȌ or ȋBȌ infrared imaging was used to develop membranes.   ȋAȌ Proteins detected by HRP-catalyzed oxidation of luminol and chemiluminescence were visualized by incubating membranes for ͳ min with ECL solution ȋTable ͳ͹Ȍ. Membranes were either exposed to an X-ray film and developed with an AGFA Curix ͸Ͳ system ȋapplicable for PDI blotsȌ or analyzed directly on a ChemiDoc Touch imaging system from Bio-Rad ȋapplicable for all other blotsȌ.   ȋBȌ Proteins detected with IRDye coupled secondary antibodies were visualized using a Li-Cor Odyssey ʹ.ͳ infrared imaging system. Protein bands were recorded by scanning light emission at ͺͲͲ nm ȋapplicable for Actin blotsȌ.   
    Table 17│Tris buffer for washing of membranes and ECL solution for protein detection 
ͷx tank buffer Tris base  ʹͶͲ mM Glycine ͳͻͷ mM HʹO  
ͳx tank buffer ͷx tank buffer ʹͲ% ȋv/vȌ Methanol ʹͲ% ȋv/vȌ HʹO  
TBS-T ȋpH ͺ.ͲȌ Tris base  ʹͶ.ͺ mM NaCl ͳͻͲ mM Tween ʹͲ Ͳ.ͳ% ȋv/vȌ HʹO  ---  
ECL solution Tris ȋpH ͺ.ͷȌ ͳͲͲ mM Luminol ʹ.ͷ mM Coumaric acid ͳ mM HʹOʹ ͳ͹ µM HʹO  
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2.8 Co-Immunoprecipitation Protein protein interactions were analyzed by co-immunoprecipitation ȋCo-IPȌ. Therefore, Jurkat cells were stimulated for ʹͶ h with test compounds, harvested, washed twice with ice cold PBS and incubated for ͵Ͳ min on ice with Triton X-ͳͲͲ lysis buffer ȋTriton buffer, Table ͳͺȌ. Proteins were cleared from cell debris by centrifugation ȋͳͲ min, ͳͲ.ͲͲͲ g, Ͷ°CȌ and supernatants were subjected to BCA protein quantification as described in section ʹ.͹.ʹ. For magnetic labeling, ͷͲͲ µg protein per sample was adjusted to ͷͲͲ µl total volume with Triton buffer and gently mixed with Ͷ µg of precipitation antibody ȋGoat anti-BAP͵ͳ C-ͳͷȌ and ͷͲ µl Protein G MicroBeads from Miltenyi Biotech for Ͷͷ min at Ͷ°C. An equal amount of BAP͵ͳ C-ͳͷ was incubated in parallel with beads, but without lysate, and served as control of antibody heavy and light chains. BAP͵ͳ and interacting proteins were co-immunoprecipitated on Miltenyi µColumns. Therefore, columns were pre-rinsed once with Triton buffer, loaded with samples, washed four times with Triton buffer and finally once with low salt wash buffer ȋTable ͳͺȌ. Proteins were eluted with ͻͷ°C pre-heated ͳx SDS sample buffer ȋTable ͳͶȌ and analyzed by immunoblotting as described in sections ʹ.͹.͵ and ʹ.͹.Ͷ. Antibodies used for detection were mouse anti-BAP͵ͳ B-ͳͲ ȋSanta CruzȌ and mouse anti-CASPͺ ͳCͳʹ ȋCell SignalingȌ.   
    Table 18│Triton X-100 lysis buffer and low salt wash buffer for Co-IP 
2.9 UV-Crosslinking, Immunostaining and Confocal Microscopy For target validation, the BAP͵ͳ protein was co-stained with the PSͺͻ photo probe ȋJP-ͲͶȌ linked to a rhodamine reporter. Hela cells ȋͲ.Ͳʹ x ͳͲ͸ cells/wellȌ were seeded in ibidi ͺ-well µ-slides, allowed to adhere for ͸ h and then incubated with ʹͲ µM JP-ͲͶ for ʹͲ min at ͵͹°C. UV crosslinking of the photoreactive aryl azide to cellular target proteins was performed with a UV lamp at ͵͸͸ nm for ͵Ͳ min at RT. Cells were fixed with ice cold Ͷ% paraformaldehyde ȋPFAȌ in RPMI cell culture medium supplemented with ͳͲ% FCS 
Triton buffer ȋpH ͺ.ͲȌ NaCl ͳͷͲ mM Tris HCl ͷͲ mM Triton X-ͳͲͲ ͳ% ȋv/vȌ Complete ʹͷx Ͷ % ȋv/vȌ HʹO  
Low salt wash buffer ȋpH ͹.ͷȌ Tris HCl ʹͲ mM HʹO  
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for ͳͷ min and then permeabilized for ͵ x ͷ min with Ͳ.ͳ% Triton X-ͳͲͲ in PBS at RT. For coupling of the rhodamine reporter dye, cells were incubated with the click reaction solution ȋTable ͳͻȌ for ʹͲ min at RT and subsequently washed three times with PBS to remove excessive dye. Immunostaining was performed with BAP͵ͳ HPAͲͲ͵ͻͲ͸ from Sigma-Aldrich overnight at Ͷ°C ȋͳ.͸ µg/ml in PBS supplemented with Ͷ% FCSȌ, Ͷ x ͳͲ min washing with PBS at RT and incubation with Anti-rabbit Alexa Ͷͺͺ AͳͳͲͲͺ from Thermo Fisher Invitrogen for ʹ h at RT in the dark ȋʹ.ͷ µg/ml in PBS/Ͷ% FCSȌ. As counterstain, Hoechst ͵͵͵Ͷʹ was added ȋc = ͷ µg/mlȌ and cells were finally washed for Ͷ x ͳͲ min with PBS before adding one drop of FluorSave mounting medium per well. Confocal microscopy was performed on a Leica SPͺ LSM system and evaluation of co-stained areas was performed with the co-localization tool of Leica LAS X software.      Table 19│Click reaction solution 
2.10 Activity-Based Protein Profiling and STRING Analysis PSͺͻ target identification was performed by Jan Vomacka in the laboratory of Prof. Stefan Sieber ȋTU Munich, GermanyȌ using an activity-based protein profiling ȋABPPȌ approach. Therefore, Jurkat cells were incubated with unmodified PSͺͻ ȋc = ͳͲͲ µMȌ or DMSO as control for Ͷͷ min at ͵͹°C and in a second step with the PSͺͻ photo probe ȋJP-ͲͶ, c = ʹͲ µMȌ or DMSO as control for Ͷͷ min at ͵͹°C. Cells were lyzed in PBS with ͳ% ȋv/vȌ NPͶͲ and ͳ% ȋw/vȌ sodium deoxycholate and sonication for ͳͷ sec on ice. Sample preparation and mass spectrometry analysis of target proteins by gel-free ABPP and dimethyl labeling was performed as previously described.͸ͺ Cutoff criteria for target identification were: ȋͳȌ enrichment by photo probe logʹ Probe/DMSO >ͳ.͸, -logͳͲ p-value >ʹ and ȋʹȌ PSͺͻ competition logʹ Probe/PSͺͻ >Ͳ.  Protein network analysis was performed using STRING vͳͲ, a web resource of protein-protein interactions that is based on experimental data, computational prediction 
Click reaction solution ͷ-TAMRA-Azide Ͳ.Ͳʹ mM CuSOͶ ͳ mM Ascorbic acid  ͳͲͲ mM PBS  
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methods and public text collections.͸ͻ The functional connection of target proteins was further refined by Gene Ontology ȋGOȌ enrichment classification.͹Ͳ 
2.11 Data Collection and Statistics Assays were performed with three technical replicates per test and data from at least three independent experiments ȋbiological replicatesȌ are expressed as mean value ± SEM. Statistical analysis and calculation of ECͷͲ values was performed with Prism ͹ software from GraphPad. For Western blot and confocal microscopy experiments, representative images of at least three independent data sets are shown. 
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3 Results 
3.1 Chemosensitization of Acute Leukemia Cells with PS89 
3.1.1 Impact on Jurkat cell apoptosis, proliferation and colony formation The concept of chemosensitization with the protein disulfide isomerase ȋPDIȌ inhibitor PSͺͻ was initially evaluated in a dose-response apoptosis assay. While PSͺͻ was applied at subtoxic concentrations ȋʹͷ µM PSͺͻ, ͹.ͺ% apoptotic cellsȌ, the dose of etoposide ȋETOȌ could be reduced at least by half to achieve equal cytotoxicity applying the combination treatment. This is in line with a shifted ECͷͲ value by ʹ.ͳ-fold ȋFigure ͺaȌ. The induction of apoptotic cell death was additionally verified by Western blotting and activation of the executioner caspase-͵ ȋCASP͵Ȍ as well as cleavage of the DNA repair enzyme poly ADP ribose polymerase ȋPARPȌ downstream of CASP͵ ȋFigure ͺbȌ.    
      a                                                                            b        Figure 8│Sensitizing effects of PS89 on Jurkat cell apoptosis. (a) Apoptosis of Jurkat cells treated with 
etoposide (ETO) in presence or absence of 25 µM PS89. Percentage of apoptotic cells was 
determined by propidium iodide staining and flow cytometry after 48 h. (b) Execution of apoptosis 
analyzed by immunoblotting. Jurkat cells were cultured for 48 h in drug supplemented medium and 
protein levels of active caspase-3 (CASP3) and poly ADP ribose polymerase (PARP) were 
determined.  Propidium iodide ȋPIȌ staining and flow cytometry revealed furthermore that PSͺͻ had no effect on cell cycle while ETO treated Jurkat cells showed pronounced Gʹ cell cycle arrest ȋFigure ͻȌ. In combination treatment, Gʹ arrest still persisted accompanied by an increase of the subGͳ apoptotic cell population featuring DNA fragmentation and therefore low PI fluorescence intensity.    
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 Figure 9│Cell cycle analysis of PS89 and ETO treated Jurkat cells. Determination of cellular DNA content of 
Jurkat cells treated for 48 h with 25 µM PS89, 0.5 µM etoposide (ETO) or combination (+/+) by 
propidium iodide staining and flow cytometry. Applying subtoxic concentrations of ETO in combination with PSͺͻ, the proliferation of Jurkat cells after ͹ʹ h treatment was inhibited more than additive ȋFigure ͳͲa, inhibition of PSͺͻ ʹͳ.ͷ% + ETO ʹ͹.ͳ% < Combination ͷͺ.ͻ%Ȍ. Moreover, the long-term effects of the combination were studied exposing Jurkat cells to a Ͷ h pulse stimulation and monitoring the ability of single cells to grow into colonies for ͹ days. As demonstrated in Figure ͳͲb, PSͺͻ and ETO both had mild effects on colony formation in single treatment ȋͺͷ% and ͺ͹% of controlȌ, tough the size and number of colony forming units ȋCFUȌ was highly decreased in combination ȋ͵ʹ% of controlȌ.  
 a                                                   b        Figure 10│Inhibition of proliferation and colony formation with PS89 and ETO. (a) Proliferation of Jurkat cells 
incubated with PS89 and etoposide (ETO). Cells were allowed to grow for 72 h, the number of viable 
cells was determined by CellTiter-Blue staining and normalized towards DMSO control. (b) Colony 
formation of Jurkat cells stimulated for 4 h with PS89 and ETO. Compounds were removed and cells 
reseeded at low density (5.000 cells/ml) in medium with increased viscosity. The number of colonies 
was quantified after 7 days of proliferation and normalized towards DMSO control.  
3.1.2 Treatment of different acute leukemia cell lines and drug resistant cells The ability of PSͺͻ to induce synergistic apoptosis with cytostatics could be translated to acute leukemia cell lines of different lineage and corresponding treatments. This was demonstrated by PSͺͻ combinations with daunorubicin ȋDNRȌ in HL-͸Ͳ AML cells and vincristine ȋVCRȌ in CCRF-CEM ALL cells ȋFigure ͳͳȌ. Furthermore, vincristine resistant 
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ȋVCR-RȌ CEM cells responded towards ͳͲͲ nM VCR in combination with PSͺͻ ȋ͵ͺ.͵% apoptotic cellsȌ, while cells were still resistant towards ͳͲ-fold higher VCR concentrations without co-stimulation ȋͳͲͲͲ nM VCR ͸.ͺ% apoptotic cells, Figure ͳͳȌ. 
 Figure 11│Chemosensitization of HL-60, CCRF-CEM and vincristine resistant (VCR-R) CEM cells. Apoptosis of ALL 
and AML cell lines treated with PS89 and cytostatics (DNR: daunorubicin, VCR: vincristine). 
Percentage of apoptotic cells was determined by propidium iodide or YO-PRO-1 staining and flow 
cytometry after 48 h. Further apoptosis studies with the vincristine resistant ALL cell line VCR-R CEM supported the results previously obtained in Jurkat cells. Combining PSͺͻ with VCR, apoptosis induction was prevented by the pan-caspase inhibitor Q-VD-OPh ȋFigure ͳʹaȌ which is in line with the activation of CASP͵ and PARP cleavage observed by Western blotting ȋFigure ͳʹbȌ. Notably, the percentage of apoptotic cells was equally high and irrespective of PSͺͻ or VCR pre-stimulation ȋFigure ͳ͵Ȍ which indicated that cell death induction by the combination treatment was rather dependent on parallel action of the compounds than a pre-sensitization of cells. 
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Figure 12│Hallmarks of apoptosis in vincristine resistant (VCR-R) CEM cells. (a) 
Apoptosis of VCR-R CEM cells treated 
with PS89 and VCR in presence or 
absence of the pan-caspase inhibitor 
Q-VD-OPh. Percentage of apoptotic cells 
was determined by propidium iodide 
staining and flow cytometry after 48 h. 
(b) Execution of apoptosis analyzed by 
immunoblotting. VCR-R CEM cells were 
cultured for 48 h in drug supplemented 
medium and protein levels of active 
caspase-3 (CASP3) and poly ADP ribose 
polymerase (PARP) were determined. 
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       The sensitizing effects of PS89 on colony formation after short-term treatment could be reproduced as well in VCR-R CEM cells. Though the cell line generally formed smaller colonies compared to Jurkat cells, the total number of colony forming units (CFU) was strongly decreased after short-term stimulation with the combination of PS89 and VCR (Figure 14).  
 Figure 14│Colony formation of vincristine resistant (VCR-R) CEM cells. After stimulation of VCR-R CEM cells for 4 h with PS89 and VCR, compounds were removed and cells reseeded at low density (5.000 cells/ml) in medium with increased viscosity. The number of colonies was quantified after 5 days of proliferation and normalized towards DMSO control. 3.1.3 Sensitization of acute leukemia patient derived xenograft cells The broad applicability of PS89 as chemosensitizing co-treatment was confirmed as a promising approach in acute leukemia patient derived xenograft (PDX) cells. AML and ALL samples of diverse background (see section 2.1.1.2) were treated with PS89 and DNR (Figure 15a) or PS89 and VCR (Figure 15b). As a result, they generally showed clearly increased apoptosis rates in combination. Yet, the standard concentration of 25 µM PS89 was non-toxic on PDX cells, which is in accordance with previous results. 
Figure 13│Apoptosis induction independent of application schedule. Apoptosis of vincristine resistant (VCR-R) CEM cells after 24 h pre-treatment with PS89 or VCR followed by 24 h co-treatment. Percentage of apoptotic cells was determined by pro-pidium iodide staining and flow cytometry.  
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Notably, low response towards the combination treatments was observed in peripheral blood mononuclear cells ȋPBMCsȌ compared to PDX samples ȋFigure ͳͷa+bȌ.       a 
 
            b                 
3.1.4 Exceptions prove the rule: antagonism of PS89 and cytarabine As the standard ͹+͵ induction chemotherapy in AML is based on the antimetabolite cytarabine ȋAra-CȌ together with an anthracycline, we tested if the chemosensitizing approach with PSͺͻ could be translated to Ara-C combinations as well. Surprisingly, PSͺͻ dose-dependently antagonized the effect of Ara-C in HL-͸Ͳ AML cells ȋFigure ͳ͸Ȍ. This result raised the question which mechanism accounted for the negative interference of PSͺͻ with Ara-C and was subjected to further discussion in combination with the PSͺͻ target screening presented in section ͵.ʹ.ʹ.   
Figure 15│Sensitization of AML and ALL patient-derived xenograft (PDX) cells with PS89. 
(a) Freshly isolated AML PDX cells and 
PBMCs treated for 72 h with PS89 and 
daunorubicin (DNR). (b) ALL PDX cells 
and PBMCs treated for 48 h with PS89 and 
vincristine (VCR). The percentage of 
apoptotic cells was determined by flow 
cytometry and specific apoptosis was 
calculated towards untreated control. 
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        Figure 16│Antagonizing effects of PS89 in combination with cytarabine (Ara-C). Apoptosis of HL-60 cells 
treated with PS89 and cytarabine (Ara-C) for 48 h. Percentage of apoptotic cells was determined by 
propidium iodide staining and flow cytometry. 
3.2 PS89 Target Network Analysis 
3.2.1 Single-target studies on protein disulfide isomerase The initial characterization of PSͺͻ revealed that the compound binds in close proximity to the catalytic center of protein disulfide isomerase ȋPDIȌ and inhibits its enzymatic activity.Ͷͻ Evaluating if this feature was responsible for the intensively pro-apoptotic cellular effects in combination with cytostatics, PDI genetic knockdown and overexpression experiments were performed. Similar to PSͺͻ, silencing of PDI did not affect basal apoptosis of Jurkat cells in non-treated cells ȋFigure ͳ͹a, DMSO controlȌ. However, no sensitizing effect of PDI silencing on etoposide ȋETOȌ induced apoptosis or inhibition of proliferation was observed ȋFigure ͳ͹a+bȌ. PDI knockdown efficiency on protein level was evaluated in parallel by Western blot ȋFigure ͳ͹cȌ.           
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        a             b           c        Figure 17│Constant levels of Jurkat apoptosis and proliferation in protein disulfide isomerase (PDI) silenced cells. 
(a) Apoptosis of PDI silenced Jurkat cells (siPDI, 48 h) treated for further 48 h with etoposide (ETO). 
Percentage of apoptotic cells was determined by propidium iodide staining and flow cytometry. 
(b) Proliferation of PDI silenced Jurkat cells (siPDI, 24 h) incubated for further 72 h with ETO. The 
number of viable cells was determined by CellTiter-Blue staining and normalized towards DMSO 
control. (c) PDI protein levels analyzed in Jurkat cells by immunoblotting after 24 h and 96 h 
transfection with non-targeting siRNA (siCtrl) or siRNA against PDI (siPDI).  In order to cross-check if PSͺͻ chemosensitizing effects were rescued by PDI overexpression, HEK ʹͻ͵ cells were chosen as convenient transfection hosts. After plasmid transfection, cells constantly expressed PDI at high protein levels ȋFigure ͳͺaȌ and were subjected to PSͺͻ and ETO stimulation. In combination treatments, PSͺͻ showed an additional inhibition of proliferation both in control and overexpressing cells ȋFigure ͳͺbȌ. Thus, increased PDI levels did not alleviate functional signaling of PSͺͻ.   A screen of PDI expression in acute leukemia cell lines revealed in addition that Jurkat as well as CEM cells featured low endogenous PDI levels compared to HL-͸Ͳ ȋFigure ͳͺcȌ. However, the chemosensitizing effects of PSͺͻ were observed in all cell lines with a fixed ʹͷ µM dose, as shown in section ͵.ͳ. In line with the overexpression study, this demonstrated once more that PDI protein levels did not correlate with sensitivity towards PSͺͻ treatment.       
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  a                b                         c          Figure 18│Protein disulfide isomerase (PDI) expression and response to PS89 combination treatment. (a) PDI 
protein levels analyzed in HEK cells by immunoblotting after 24 h and 96 h transfection with empty 
vector pcDNA3.1 (pCtrl) or PDI vector (pPDI). (b) Proliferation of PDI overexpressing HEK cells (pPDI, 
24 h) incubated for further 72 h with PS89 and etoposide (ETO). The number of viable cells was 
determined by CellTiter-Blue staining and normalized towards DMSO control. (c) PDI expression in 
acute leukemia cell lines determined by immunoblotting. In summary, PDI silencing did neither sensitize cells towards ETO treatment, nor did overexpression of PDI rescue the functional effect of PSͺͻ. This indicated a more extensive pharmacodynamic profile of PSͺͻ.  
3.2.2 Activity-based protein profiling of PS89 target proteins In order to identify the proposed PSͺͻ polytarget structure, activity-based protein profiling ȋABPPȌ was applied in Jurkat cells as depicted in Figure ͳͻ. First, the PSͺͻ photo probe modified by an alkyne handle ȋstructure shown in Figure ͳͻȌ was covalently linked to cellular targets in presence or absence of PSͺͻ. Co-incubation with the unmodified compound acting as a competitor was performed to exclude the identification of targets that were only enriched by the probe, but not by PSͺͻ. Subsequently, target proteins were enriched by biotin-avidin-pulldown, digested, labeled and analyzed by mass spectrometry ȋMSȌ. Sample preparation and MS analysis was performed as described in section ʹ.ͳͲ by Jan Vomacka ȋgroup of Prof. Stefan Sieber, TU Munich, GermanyȌ.     
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 Figure 19│Principle of target identification by activity-based protein profiling (ABPP). Jurkat cells were 
incubated with unmodified PS89 (c = 100 µM) or DMSO as control and in a second step with the PS89 
photo probe (c = 20 µM). After cell lysis, biotin was conjugated to the alkyne group by cycloaddition 
and target proteins were identified by avidin pulldown, tryptic digestion and mass spectrometry. 
Scheme adapted from Vomacka et al.68 Raw data of the ABPP target identification accompanies this thesis as outlined in the appendix section ͺ.ʹ. Illustrated in Figure ʹͲa, logʹ-fold protein enrichments in photo probe samples compared to DMSO baseline levels were plotted against their statistical significance expressed as p-values. In the resulting volcano plot, proteins localized at the central symmetric part were unspecific binders, while the hits in the blue-colored area featured a >͵-fold enrichment by the photo probe with p-values <Ͳ.Ͳͳ. This selection was further refined by the ability of PSͺͻ to compete with the probe at the binding sites of the target proteins and is expressed by the size and coloring of dots in Figure ʹͲb. In total, n = Ͷʹ target proteins were identified and ranked according to the degree of probe enrichment and PSͺͻ competition ȋTable ʹͲȌ.       
  a        b             Figure 20│Volcano plot of PS89 target proteins. (a) Proteins enriched by the PS89 photo probe compared to 
basal protein levels (DMSO control). Targets enriched >3-fold (log2 Enrichment Probe / DMSO >1.6) and with -log10 p-value >2 are highlighted. (b) Competition of PS89 at photo probe binding sites. Proteins enriched by the photo probe (‘Probe’), but depleted after PS89 pre-treatment (‘PS89’) are 
accentuated with increasing dot size (log2 Enrichment Probe / PS89) and color intensity (-log10 p-value Probe / PS89). 
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BAP31 
=
PDIA1 
=
Pathway ID Pathway
Description
Count in 
Gene Set
FDR
Cellular Component (GO)
GO:0005783 EndoplasmaticReticulum 22 5.9e-12
Biological Process (GO)
GO:0045454 Cell RedoxHomeostasis 8 6.7e-09
GO:0019725 CellularHomeostasis 13 9.1e-07
3.2.3 Target network and Gene Ontology analysis Evaluating the polypharmacological profile of PSͺͻ, protein-protein interaction analysis was performed using the STRING database.͸ͻ As shown in Figure ʹͳa, ʹ͵ out of Ͷʹ PSͺͻ target proteins were involved in a network with significantly more interactions than expected for a random set of proteins drawn from the genome. As this enrichment indicated that the proteins are biologically connected, the network was further analyzed by Gene Ontology ȋGOȌ functional classification for common cellular components ȋGO CCȌ and biological processes ȋGO BP, Figure ʹͳbȌ.͹Ͳ Regarding GO CC, a highly significant number of PSͺͻ target proteins ȋn=ʹʹ, FDR ͷ.ͻe-ͳʹȌ was localized in the endoplasmic reticulum ȋorange circlesȌ. Functionally, proteins involved in ǮCellular Homeostasisǯ and in particular ǮCell Redox Homeostasisǯ were highly enriched in the data set of PSͺͻ targets in Jurkat cells ȋFDR ͻ.ͳe-Ͳ͹ and ͸.͹e-ͲͻȌ. Exhibiting high overall scores ȋsee Table ʹͲȌ, these terms included PDIAͳ ȋgene name PͺHBȌ, a number of further PDI isoforms that have been linked with chemoresistance,Ͷͷ, ͹ͳ and the B-cell receptor-associated protein ͵ͳ ȋBAP͵ͳ, gene name BCAP͹1Ȍ. 
a 
 
 
 
 
 
 
  
b       
Figure 21│STRING network of PS89 target proteins. 
(a) Protein-protein interaction analysis of 
PS89 target proteins (n=42) by the web 
resource STRING v10. Line thickness 
indicates the strength of data support. (b) 
Functional enrichment analysis of the STRING 
network by Gene Ontology (GO) classification. 
Most prominent terms of GO Cellular 
Component (orange circles) and GO Bio-
logical Process (green dots) are highlighted. 
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3.3 Signal Transduction via the BAP31-Caspase-8 Axis Summarizing sections ͵.ͳ and ͵.ʹ, apoptosis of acute leukemia cells was not induced 
per se targeting the ER redox environment with PSͺͻ, but was rather dependent on the stimuli of cytostatics. Inquiring how those induce cell death, the majority of cytostatics has in common that the mitochondrial pathway plays the predominant role for the execution of apoptosis.͹ʹ-͹Ͷ Therefore, we hypothesized dynamics between the ER and mitochondria in PSͺͻ combination treatments and particularly expected a crucial function of the B-cell receptor-associated protein ͵ͳ ȋBAP͵ͳȌ. This protein is a major pro-apoptotic communicator at the interface of ER and mitochondriaʹ͸, ͹ͷ as well as one of the most prominent PSͺͻ targets ȋFigure ʹͲ and Table ʹͲȌ. 
3.3.1 Co-staining of the PS89 photo probe and BAP31 For BAP͵ͳ target validation, a co-staining was performed using a BAP͵ͳ-specific antibody and the PSͺͻ photo probe linked to a rhodamine reporter ȋͷ-TAMRA-AzideȌ by click chemistry. Besides the supposed ER specificity of both, overlapping fluorescence was computed and revealed distinct co-localized ER network structures of PSͺͻ photo probe-rhodamine ȋredȌ and BAP͵ͳ-Alexa Ͷͺͺ ȋgreen, Figure ʹʹaȌ. This suggested a consolidated binding to the same protein target. Analyzed in parallel, no background staining of either the Alexa Ͷͺͺ secondary antibody or the dye ͷ-TAMRA-Azide was detected ȋFigure ʹʹbȌ.              
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     a        b 
 Figure 22│Co-localization of BAP31 and the PS89 photo probe. (a) Immunofluorescence staining of B-cell receptor-associated protein 31 (BAP31, green) and the PS89 photo probe linked to a rhodamine reporter (5-TAMRA-Azide, red) in Hela cells. Representative original confocal microscopy images (upper row) and areas of co-localization analyzed with Leica LAS X software (lower row) are shown. (b) Left column: control of secondary antibody background with respect to BAP31 primary + secondary antibody staining (Sec Ab + BAP31). Right column: control of 5-TAMRA-Azide background with respect to PS89 photo probe samples after UV crosslinking and coupling to the rhodamine reporter (5-TAMRA-Azide + Probe). Nuclei were stained with Hoechst 33342. 3.3.2 Cleavage of BAP31 and caspase-8 in PS89 and etoposide treated cells Following the hypothesis of a BAP31 dependent pathway linking ER redox disturbance and signaling of cytostatics, the cleavage of BAP31 into the pro-apoptotic p20BAP31 fragment was analyzed. Considering that caspase-8 (CASP8) executes BAP31 cleavage, the expression and processing of CASP8 was evaluated concurrently. In PS89 and ETO combination treated cells, an increased CASP8 activity represented by p43/41 cleavage products was detected compared to ETO single treatment (Figure 23a). Moreover, cleavage of BAP31 was only present in PS89 combination treated cells and, as an early trigger, already visible after 24 h stimulation (Figure 23b).  a             b     Figure 23│Cleavage of endogenous CASP8 and BAP31. Jurkat cells treated with PS89 and etoposide (ETO) were subjected to Western blot analysis. (a) Protein level of the caspase-8 (CASP8) zymogen and the cleavage products p43/41 CASP8 determined after 24 h and 48 h. (b) Protein level of B-cell receptor-associated protein 31 (BAP31) and the cleavage product p20BAP31 determined after 24 h and 48 h. 
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Ab
BAP31 IP       Ctrl
CASP8
p43/41
CASP8
BAP31
Loading
PS89 [µM]    - 25        - 25       -
ETO [µM]    - - 0.5      0.5   -
3.3.3 Co-immunoprecipitation of the BAP31-caspase-8 complex It has been shown previously that BAP͵ͳ within a protein complex serves as a platform for CASPͺ activation upon apoptotic stimuli and death effector domain ȋDEDȌ interactions.ʹͻ Hence, the influence of PSͺͻ on the BAP͵ͳ-CASPͺ association was examined. In co-immunoprecipitated samples ȋBAP͵ͳ pulldownȌ, pro-CASPͺ was associated with BAP͵ͳ independently of treatment. Though cleaved pͶ͵/Ͷͳ CASPͺ was only detected in the presence of both stimulants, PSͺͻ and ETO ȋFigure ʹͶȌ. The BAP͵ͳ antibody incubated without lysate served as control of heavy and light chains which were detected on the protein gel ȋLoadingȌ, but not on the blot ȋLane ͷ, Ab CtrlȌ.       
3.3.4 Suppression of apoptosis by caspase-8 inhibition In order to provide further evidence that apoptosis induced by PSͺͻ and ETO combination treatments is critically dependent on CASPͺ activity, cells were stimulated in presence of the irreversible CASPͺ inhibitor Z-IETD-FMK, which dose-dependently reduced the number of apoptotic cells ȋFigure ʹͷaȌ. The specificity of Z-IETD-FMK was confirmed by immunoblot analysis of CASPͺ showing reduced auto-catalytic activity and pͶ͵/Ͷͳ cleavage, respectively. In accordance, the ratio of apoptotic cells in PSͺͻ combination versus ETO single treatment was lower in CASPͺ deficient Jurkat cells ȋFigure ʹͷb, ͳ.͹-fold in CASPͺ -/- Jurkat vs. ʹ.ͺ-fold in wildtype Jurkat cellsȌ. The stable CASPͺ knockout was confirmed by Western blot ȋFigure ʹͷbȌ.         
Figure 24│Co-immunoprecipitation of BAP31, pro- and cleaved CASP8. 
B-cell receptor-associated protein 31 (BAP31) was pre-
cipitated from Jurkat cell lysates after 24 h stimulation with 
PS89 and etoposide (ETO). Blots were probed for BAP31 and 
caspase-8 (CASP8). BAP31 antibody served as control of 
heavy and light chains and an equal amount of precipitation 
antibody was confirmed on stainfree gels (loading). 
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 Figure 25│Decreasing apoptosis by CASP8 inhibition or knockout. (a) Apoptosis of Jurkat cells treated with 
PS89 and etoposide (ETO) in presence of the specific caspase-8 (CASP8) inhibitor Z-IETD-FMK after 
48 h. Percentage of apoptotic cells was determined by propidium iodide staining and flow cytometry. 
Protein expression of CASP8 and the cleavage products p43/41 CASP8 was determined by Western 
blot. (b) Apoptosis of CASP8 deficient (CASP8 -/-) or wildtype Jurkat cells treated with PS89 25 µM 
and ETO (250 nM and 500 nM, respectively) for 48 h. Percentage of apoptotic cells was determined 
by propidium iodide staining and flow cytometry. Knockout of CASP8 was verified by Western Blot. 
3.3.5 Prevention of PS89 chemosensitization by BAP31 silencing As the activation of the BAP͵ͳ-CASPͺ-axis was now clearly demonstrated in PSͺͻ combination treatments, the consequence of BAP͵ͳ silencing, supposed to disable binding of PSͺͻ to its direct target, was studied. In control transfected cells ȋsiCtrlȌ, PSͺͻ was able to significantly increase ETO triggered apoptosis as expected. However, BAP͵ͳ knockdown ȋsiBAP͵ͳȌ prevented additional cytotoxicity of the combination compared to ETO single treatment ȋFigure ʹ͸Ȍ. Efficient siRNA knockdown of BAP͵ͳ was determined in parallel by immunoblotting.  
  Figure 26│Non-significant effect of PS89 in BAP31 silenced cells. Apoptosis of Hela cells transfected with non-
targeting siRNA (siCtrl) or BAP31 specific siRNA (siBAP31). 6 h post-transfection, cells were treated 
with PS89 and etoposide (ETO) for 48 h. Percentage of apoptotic cells was determined by propidium 
iodide staining and flow cytometry. Statistics: One way ANOVA, Bonferroni, p<0.01. Silencing of 
BAP31 was verified by Western blot.  
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3.4 Pro-Apoptotic Crosstalk at the ER-Mitochondrial Interface 
3.4.1 Elevation of cytosolic calcium levels A consequence of BAP͵ͳ cleavage is calcium release from the ER mediating ER-mitochondrial crosstalk.ʹͻ, ͵ͳ A shifted Cal-ͷʹͲ fluorescence intensity and thus higher cytosolic calcium levels were observed in PSͺͻ combination treated cells after Ͷͺ h compared to ETO single treatment ȋFigure ʹ͹aȌ. Further, a time-dependent analysis of intracellular calcium was performed normalizing the Cal-ͷʹͲ mean fluorescence intensity to DMSO control. Interestingly, amplification of calcium release was observed from ʹͶ h to Ͷͺ h in PSͺͻ combination, but not ETO single treated cells ȋFigure ʹ͹bȌ. 
     a                    b 
 
 
 
 
 
 
 Figure 27│Time-dependent increase of intracellular calcium levels. (a) Fluorescence intensity of Cal-520 
determined by FACS analysis of Jurkat cells after 48 h treatment (dotted grey line: unstained control, 
grey: DMSO, green: PS89 25 µM, blue: etoposide (ETO) 0.5 µM, red: combination). (b) Mean values 
of Cal-520 fluorescence intensity normalized to DMSO control after 24 h and 48 h treatment.  
3.4.2 Dissipation of mitochondrial membrane potential and intrinsic apoptosis Mitochondria are able to buffer high levels of cytosolic calcium, though an overload and prolonged opening of the permeability transition pore ȋMPTPȌ coincide with disruption of the mitochondrial membrane potential ȋΔΨmȌ.͹͸ The ratio of cells with intact and dissipated ΔΨm is therefore indicative for mitochondrial damage. Using the dye JC-ͳ which exhibits ΔΨm-dependent aggregation, mitochondrial depolarization was demonstrated by a decrease in the red/green fluorescence ratio in PSͺͻ and ETO treated Jurkat cells after Ͷͺ h ȋFigure ʹͺaȌ. In addition, a quantification of the cell population with dissipated membrane potential confirms that mitochondrial damage is highly increased by co-incubation of ETO with PSͺͻ ȋFigure ʹͺb, ʹͶ h: ETO ͻ% vs. Combination ͳͻ%; Ͷͺ h: ETO ʹͳ% vs. Combination ͷͷ%Ȍ. 
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 Figure 28│Disruption of the mitochondrial membrane potential (ΔΨm). (a) JC-1 staining and FACS analysis of 
Jurkat cells after 48 h treatment (grey: DMSO, green: PS89 25 µM, blue: etoposide (ETO) 0.5 µM, 
red: combination). Two populations with intact or dissipated ΔΨm are distinguished dependent on the 
PE (red) / Alexa (green) fluorescence ratio. (b) Quantification of Jurkat cells with dissipated ΔΨm after 
24 h and 48 h treatment.  Mitochondrial apoptosis proceeds upon the assembly of the pro-apoptotic proteins Bax and Bak into oligomeric pore complexes which trigger mitochondrial outer membrane permeabilization ȋMOMPȌ. As a tightly regulated process, MOMP is further under control of several Bcl-ʹ family proteins including anti-apoptotic Bcl-ʹ and Bcl-xL. As shown in Figure ʹͻa, Jurkat cells overexpressing Bcl-ʹ or Bcl-xL were significantly less sensitive towards PSͺͻ combination treatments than the empty vector cell line Jurkat/neo. This demonstrated that cell death was effectively executed only upon functional mitochondrial apoptosis signaling. The overexpression of anti-apoptotic proteins in Jurkat/Bcl-͸ and Jurkat/Bcl-xL cells was confirmed by Western blot ȋFigure ʹͻbȌ.   As a result of MOMP, pro-apoptotic factors such as cytochrome c ȋCyt cȌ are released from the intermembrane space of mitochondria into the cytosol. Therefore, a separation of mitochondria from cytosolic fractions was performed prior to immunoblot analysis. For the purity of fractions, the voltage-dependent anion channel ȋVDACȌ was indicative as it is located at the outer mitochondrial membrane and was not detected in the cytosolic part ȋFigure ʹͻcȌ. In contrast, Cyt c was found in the cytosol of PSͺͻ and ETO combination treated cells which supported the significance of apoptosis execution via the intrinsic pathway ȋFigure ʹͻcȌ.    
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        c    Figure 29│Mitochondrial apoptosis. (a) Suppression of apoptosis induction in Jurkat cells overexpressing 
Bcl-2 (Jurkat/Bcl-2) or Bcl-xL (Jurkat/Bcl-xL) compared to the empty vector cell line (Jurkat/neo). Cells 
were treated with PS89 and etoposide (ETO) for 48 h. Percentage of apoptotic cells was determined 
by propidium iodide staining and flow cytometry. (b) Verification of Bcl-2 and Bcl-xL overexpression by 
Western blot. (c) Cytochrome c (Cyt c) protein levels in cytosolic (Cyto) and mitochondrial (Mito) 
fractions analyzed by Western blot after treatment of Jurkat cells with PS89 and ETO for 48 h. The 
voltage-dependent anion channel (VDAC) was analyzed in parallel to verify Cyto-Mito fractionation. 
3.4.3 Generation of reactive oxygen species Mitochondrial damage is accompanied by an accumulation of reactive oxygen species ȋROSȌ.͹͹, ͹ͺ Using the redox-sensitive dye Carboxy-HʹDCFDA, ROS induction by ETO was verified and ROS levels were further amplified in combination treatment with PSͺͻ ȋFigure ͵ͲaȌ. This was quantified normalizing the shift of DCF fluorescence intensity towards DMSO control ȋFigure ͵Ͳb, mean intensity ETO: ͺͳ͸ vs. PSͺͻ + ETO: ͳ͵ͷ͸Ȍ. ROS signaling from mitochondria to the ER provokes further disturbance of ER redox homeostasis and finally closes the feedback loop. 
         a                         b        Figure 30│PS89 mediated amplification of ROS production. (a) Jurkat cells treated for 24 h or 48 h with PS89 
and etoposide (ETO) were loaded with the redox sensitive dye Carboxy-H2DCFDA and analyzed by flow cytometry. Intracellular reactive oxygen species (ROS) levels are expressed as mean values of 
DCF fluorescence intensity normalized to DMSO control. (b) Representative overlay of DCF 
fluorescence curves determined by flow cytometry after 48 h treatment (dotted grey line: unstained 
control, grey: DMSO, green: PS89 25 µM, blue: ETO 0.5 µM, red: combination). 
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3.5 Summary In summary, PSͺͻ highly increases the effectiveness of cytostatics through a crosstalk and mutual amplification of pro-apoptotic stress triggers promoting mitochondrial apoptosis ȋFigure ͵ͳȌ. This is achieved by directly targeting a network of ER homeostasis proteins which is depicted by the main targets BAP͵ͳ and PDI in the graphical summary. BAP͵ͳ critically contributes to the communication from ER to mitochondria resulting from cleavage into pʹͲBAP͵ͳ by active caspase-ͺ and subsequent calcium release, both explicitly favored in presence of the chemosensitizer PSͺͻ. Thus, the present study discloses the potential of dually targeting the ER-mitochondrial apoptosis network as a novel and strongly synergistic drug combination strategy. 
 Figure 31│Communication at the ER-mitochondrial interface of cell death in PS89 combination treatments. The 
polypharmacological profile of the small molecule compound PS89 targeting a network of ER 
homeostasis proteins is represented by its main targets PDI and BAP31. Upon apoptotic stimuli of 
cytostatics and exclusively in presence of PS89, BAP31 is cleaved by caspase-8 to pro-apoptotic 
p20BAP31. Subsequent calcium release from the ER and increased ER stress promote loss of 
mitochondrial membrane potential (ΔΨm) and mitochondrial apoptosis. In turn, elevated production of 
reactive oxygen species (ROS) feeds back to the ER and is able to provoke further ER stress and 
calcium release. The mutual amplification of ER-mitochondrial stress triggers finally leads to 
synergistic activation of executioner caspases and apoptosis in the combinatory treatment approach 
with cytostatics and the chemosensitizer PS89. 
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4 Discussion 
4.1 PS89: a Drug Candidate for Combination Therapies  
4.1.1 Chemosensitization of acute leukemia cells This work reveals that activating the apoptotic machinery at the ER-mitochondrial interface by PSͺͻ and cytostatics is a highly favorable strategy to sensitize acute leukemia cells. Strikingly, the term chemosensitization applies here as PSͺͻ demonstrated the ability to increase the effectiveness of chemotherapeutics although the compound itself was employed at subtoxic concentrations in all assays.   Motivated by the initial observation that PSͺͻ sensitized Jurkat cells towards etoposide treatment, the concept was successfully transferred to further acute leukemia models. Here, the co-stimulation with PSͺͻ resulted in a highly synergistic apoptosis response in ALL and AML cell lines, drug resistant and patient derived xenograft ȋPDXȌ cells. In particular, PSͺͻ was able to sensitize relapsed AML PDX cells with poor prognostic features.ͷ͹ As the doses of chemotherapeutics could be reduced at least by half in combination with PSͺͻ while maintaining efficacy, this approach may especially be interesting for the treatment of acute leukemia patients unable to receive intensive chemotherapy. Indeed, there remains a significant unmet need for novel therapeutic strategies in this subgroup and as one promising approach, the combination of low-intensity treatments with novel agents has been proposed.ͳͻ  
 The positive interference of PSͺͻ with cytostatics was at the same time not limited to etoposide, but also achieved in combination with daunorubicin and vincristine. Of note, drugs targeting ER homeostasis constitute a novel compound class which is supposed to be successful independent of major ALL and AML mutations and may serve as a powerful option to overcome resistances against established drugs. At lower concentrations of cytostatics, the combination with PSͺͻ additionally resulted in strongly inhibited proliferation and colony formation of leukemia cells. Altogether, this broad applicability and favorable chemosensitizing properties qualify PSͺͻ as a promising drug candidate.   
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4.1.2 Directions in PS89 drug development In order to exploit the full potential of PSͺͻ, two major issues were envisaged for further drug development: ͳȌ the mechanistic background of the synergistic interaction which was particularly addressed in the present work and ʹȌ the pharmacokinetic and pharmacodynamic characterization of PSͺͻ in vivo which will be briefly discussed in the following section.  A precondition for in vivo studies is the demonstration of PSͺͻ safety and the evaluation of appropriate dosing. At the current stage, this point is supported by an initial toxicity test of our lab that showed good tolerability of PSͺͻ after daily i. p. injection of ͳͲ - ͵Ͳ mg/kg doses into SCID mice.͹ͻ Then, pharmacokinetic studies are required as the bioavailability and metabolism of PSͺͻ remain open issues so far. At least from a structural point of view, PSͺͻ features suitable druglike properties and satisfies the Lipinski rule of five indicating oral bioavailability. Regarding pharmacologic interactions, the present study already recognized a therapeutically relevant antagonism of PSͺͻ with cytarabine ȋAra-CȌ. This is likely based on the binding of PSͺͻ to the equilibrative nucleoside transporter ͳ ȋENTͳ, gene name SLC͸9AͷȌ which was identified in the proteomics target screening. This presumably blocks the transport capacity of ENTͳ which is responsible for the cellular uptake of Ara-C. Finally, the efficacy as well as dose-response relationship of PSͺͻ in combination with cytostatics needs to be evaluated 
in vivo. Here, it is envisaged that established leukemia models of patient-derived cells growing in mice will be of special prognostic value.ͷ͸, ͷ͹   Approaching to the mechanistic point of the agenda, several conclusions could be drawn already from the functional in vitro data. The activity of PSͺͻ in several cell culture models indicated a broadly applicable rather than cell-type specific signaling. This was critically dependent on an apoptotic trigger by cytostatics, though independent of their direct targets. And as finally shown by pre- versus co-stimulation experiments, apoptosis induction of PSͺͻ combinations was most effective and therefore basically relied on the concurrent interaction of both compounds. Aiming to elucidate this crosstalk, the present work on PSͺͻ targets will be discussed with reference to the current understanding of chemotherapy response. 
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4.2 Determinants of Response to Chemotherapy It is well-established that the majority of classic cytostatics initiate apoptosis via the mitochondrial pathway.͹ʹ-͹Ͷ However, it has been poorly understood which mechanisms account for the differential success of chemotherapy between individuals and why some cells are more sensitive than others. In an approach to answer this question, the response to chemotherapy was recently correlated with the distinct proximity of cellsǯ mitochondria to the apoptotic threshold, a property called mitochondrial priming.ͺͲ, ͺͳ This Ǯreadiness for apoptosisǯ was defined by the balance of pro- and anti-apoptotic buffers within a cell and governed by the Bcl-ʹ family. As it has been shown that acute leukemias are among the most highly primed cancers, they are generally more chemosensitive than others.ͺͲ Moreover, the therapeutic index in AML was in fact determined by the priming of myeloblasts relative to normal hematopoietic stem cells.ͺʹ Translated to the present findings that ALL and AML PDX cells were more vulnerable towards PSͺͻ combination treatments than PBMCs, it is conceivable that their pretreatment priming accounts for the discrete sensitivity. In terms of the mechanistic PSͺͻ study, it is however even more important to note that mitochondria are not only the main executers of apoptosis, but also gatekeepers which determine the sensitivity towards cytotoxic chemotherapy.  As outlined in section Ͷ.ͳ, we could increase the sensitivity of even chemoresistant leukemic cells with PSͺͻ and cytostatics, which was accompanied by activation of the executioner caspase-͵ and cleavage of the DNA repair enzyme PARP. Notably, not only these downstream hallmarks of apoptosis, but also the dissipation of the mitochondrial membrane potential as well as cytochrome c release from mitochondria was strongly supported by the co-treatment with PSͺͻ. This was of interest as the proteomics target screen revealed that the most prominent PSͺͻ target proteins were located at the ER. In line, PSͺͻ has been shown to inhibit the ER-resident protein disulfide isomerase ȋPDIȌ previously.Ͷͻ Thus, we envisaged that PSͺͻ affected the mitochondrial apoptosis threshold or priming, respectively, through an ER triggered input to the intrinsic pathway. Henceforward, this hypothesis was subjected to further investigation and the most apparent way guided us to the prominent PSͺͻ target PDI at first.   
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4.3 PDI Inhibition and the PS89 Target Network It is common understanding that PDI inhibitors act by accumulating misfolded proteins which leads to ER stress, activation of the unfolded protein response ȋUPRȌ and cell death.Ͷʹ, Ͷ͹, Ͷͺ As the connection from the UPR to the mitochondrial apoptotic pathway is well-established,ʹͶ this link seemed conclusive to explain the sensitizing effects of the PDI inhibitor PSͺͻ. However, no induction of ER stress or UPR was observed in our previous study applying PSͺͻ at subtoxic concentrations, but only together with etoposide.Ͷͻ This indicated that activation of the ER stress response is not primary induced by PSͺͻ, but rather results from the disability of the ER to resolve a stress condition triggered by PSͺͻ in cooperation with cytostatics.  Hence, the causative responsibility of the PSͺͻ main target PDI for the chemosensitizing effects was evaluated. Surprisingly, PDI silencing had no effect on Jurkat cell viability or the sensitivity of cells towards etoposide treatment. The consequences of PDI knockdown are however controversially discussed in literature concerning the direct effect of PDI silencing,Ͷ͹, ͺ͵ as well as the ability to sensitize cancer cells.͹ͳ, ͺͶ The feasibility of a single PDI knockdown was additionally questioned by another report because many ER stress chaperones feature PDI activity as well. The authors therefore proposed to overexpress PDI instead and evaluate if this abrogated the functional effect of PDI inhibitors.ͺͷ This strategy was not successful to rescue PSͺͻ activity either, but correlated with the observation that the effectiveness of PSͺͻ was entirely independent of PDI expression in leukemia cell lines. So, we concluded that the strong sensitizing properties were rather a result of polypharmacology than single-targeting of PDI.  This was supported by the PSͺͻ activity-based protein profiling ȋABPPȌ approach in conjunction with STRING network analysis. It revealed a total of ͹ PDI family members targeted by PSͺͻ including PDIA͵, PDIAͶ and PDIA͸ which all potentially mediate chemoresistance and were recognized as promising drug targets previously.Ͷͷ, ͹ͳ Moreover, a recent report highlighted that the function of PDIA͸ is not restricted to protein folding, but also controls UPR signaling by direct interaction with the ER stress sensor IREͳα.ͺ͸ As a consequence, a higher responsiveness to ER stress and decreased proliferation was observed in PDIA͸ depleted cells. This direct involvement in the 
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control of the UPR uncovered a novel perspective on the function of PDIs and encourages their further investigation as physiologic regulators as well as drug targets.  Taking into account that the ͹ PDI isoforms were further meshed in a PSͺͻ target network of overall ʹ͵ proteins, it seems likely that this broad-spectrum targeting of ER homeostasis finally imparts PSͺͻ the ability to mediate the robust sensitizing effects that have been observed. In a broader context, this opinion supports the argumentation for network pharmacology to combat complex diseases such as cancer.ͷͲ, ͺ͹ In this conception, multi-target strategies rather than the Ǯone drug, one targetǯ paradigm are proposed to be superior to rewire cancer-specific networks.ͺͺ, ͺͻ Adopting this network view to elucidate how combination therapy works, it remains interesting how drugs interact beyond the border of subcellular compartments. This leads back to the still pending question, namely how PSͺͻ and cytostatics finally cooperate to activate the UPR and stimulate mitochondrial apoptosis.  
4.4 Bidirectional Communication at the ER-Mitochondrial Interface Summarizing sections Ͷ.ʹ and Ͷ.͵, PSͺͻ targets a network of proteins in the ER, while mitochondria critically determine the response towards cytotoxic chemotherapy. The integrity of mitochondria and the intrinsic pathway of apoptosis are regulated by a sophisticated array of checks and balances. These are in turn significantly influenced by the capability of the ER to either buffer cellular stress conditions or switch to pro-death signaling upon irreparable ER stress. This close relation of ER and mitochondria has been thoroughly reviewed resulting in the notion that cell fate is essentially dependent on the crosstalk of apoptotic signaling at the ER-mitochondrial interface.ʹͶ-ʹ͹  Applying cytostatics together with the ER targeting compound PSͺͻ, we demonstrate here that the concept of ER-mitochondrial Ǯamplification by communicationǯ can be exploited for combination therapy. This statement is based on data disclosing a strong induction of calcium and ROS as well as pro-apoptotic signaling via the ER resident B-cell receptor-associated protein ͵ͳ ȋBAP͵ͳȌ. Depicting how they are interconnected, this set of data will be discussed with reference to literature. 
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Stimulating cells with PSͺͻ combinations, the primary events affecting mitochondria are most likely triggered by cytostatics in a pͷ͵-dependent manner or by direct binding to mitochondria complex I, a novel mechanism shown for DNA-targeting agents recently.͹ͺ This promotes the accumulation of mitochondrial ROS, which is in accordance with the present data showing elevated ROS levels in etoposide treated cells. Alternatively, cytostatics bridge the ER-mitochondrial interface via the mitochondrial fission ͳ protein ȋFisͳȌ which has been demonstrated to form a complex with BAP͵ͳ and facilitate the caspase-ͺ ȋCASPͺȌ mediated cleavage into pʹͲBAP͵ͳ.ʹͻ Analyzing this route in the present work, PSͺͻ in combination with etoposide highly enhanced the activation of CASPͺ which coincided with BAP͵ͳ cleavage. Of note, the cleavage of endogenous BAP͵ͳ was not only shown with cytostatics previously, but also with the ER stress inducer Brefeldin A.͵ʹ We therefore anticipate that ER redox disturbance by mitochondrial ROS and PDI inhibition by PSͺͻ highly support the processing of BAP͵ͳ.   Temporally, BAP͵ͳ cleavage and consequent calcium release from the ER have been identified as early events in apoptosis signaling from mitochondria to ER and back.ʹͻ  Indeed, the processing of BAP͵ͳ was observed in co-treated cells already after ʹͶ h. Subsequently, an amplification of calcium release was shown between ʹͶ h and Ͷͺ h in PSͺͻ combination, but not etoposide single treated cells. This supports that PSͺͻ is the main actor to establish ER-driven feedback. Mitochondria-directed calcium flux finally promotes mitochondrial outer membrane permeabilization ȋMOMPȌ and cytochrome c release,ʹͶ, ʹ͹ which was demonstrated to be increased in PSͺͻ co-stimulated cells as well.   In summary, PSͺͻ is able to augment apoptotic triggers of cytostatics by lowering the threshold to tune pro-apoptotic feedback from the ER. With reference to the concept of S. Grimm who specified the ER-mitochondrial Ǯsocial network of cell deathǯ,ʹͷ it is conceivable that this feedback achieves the significant amplification effect by reaching numerous mitochondria for cell death induction, even if the original cytostatics stimulus targeted only a few. PSͺͻ could therefore stably intensify the response towards cytostatics treatment in a variety of acute leukemia cell lines and PDX cells. This altogether discloses the potential of targeting the ER-mitochondrial apoptosis network as a novel and strongly synergistic drug combination strategy. 
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4.5 PS89 as the First Small-Molecule Compound Targeting BAP31 It was now clearly demonstrated that the highly positive interference of PSͺͻ with the signaling of cytostatics happens at the ER-mitochondrial interface. An implication of BAP͵ͳ in the crosstalk of PSͺͻ with cytostatics was identified in addition. However, one aspect that made us especially curious about BAP͵ͳ was not addressed so far. It is the fact that BAP͵ͳ was not only mediator, but also a direct target of PSͺͻ. The binding of PSͺͻ to BAP͵ͳ was initially recognized by the proteomics target screen and according to the ranking score, BAP͵ͳ was among the three most highly enriched proteins. This was validated by a staining of the PSͺͻ photo probe with a BAP͵ͳ-specific antibody showing consolidated binding to the same target. In order to understand how the binding of PSͺͻ influences BAP͵ͳ, a closer examination of the BAP͵ͳ protein complex is required. As already mentioned, Fisͳ was shown to form a tripartite complex with BAP͵ͳ and caspase-ͺ ȋCASPͺȌ.ʹͻ This complex seems to be further under control of the cell death-inducing pͷ͵-target protein ͳ ȋCDIPͳȌ as well as the anti-apoptotic proteins Bcl-ʹ and Bcl-xL.͵ʹ However, the dynamics which regulate the balance of pro- and anti-apoptotic proteins within the complex have not been clarified yet.   PSͺͻ is to our knowledge the first BAP͵ͳ binding small-molecule compound described and was shown to facilitate BAP͵ͳ cleavage upon cytostatics stimuli. Thus, we propose that PSͺͻ may serve as a valuable tool to study the complex dynamics and to manipulate BAP͵ͳ interactions that favor the pro-apoptotic output. While an option to realize this project will be discussed in section Ͷ.͸, the particular interaction of BAP͵ͳ with CASPͺ was already addressed in the present study.   BAP͵ͳ is a substrate of CASPͺ but at the same time, the BAP͵ͳ protein complex has been identified to serve as a platform for CASPͺ activation.ʹͻ This is based on a variant death effector domain ȋvDEDȌ that was recognized in BAP͵ͳ and responsible for the interaction with CASPͺ.ʹͻ, ͻͲ Here we show for the first time the intermediate pͶ͵/Ͷͳ cleavage product of CASPͺ associated with BAP͵ͳ, which still holds a DED-domain for DED-DED interaction. This supports the suggestion of Iwasawa et al. ʹͻ that further processing into the finally active pͳͺ fragment in fact happens at the BAP͵ͳ complex. Thus, the activation of CASPͺ independent of an extrinsic stimulus likely accounts for the 
 D I S C U S S I O N     62 
  
critical role of CASPͺ in the apoptosis signaling of PSͺͻ combination treatments. This was demonstrated by significantly decreased apoptosis rates in presence of the CASPͺ inhibitor Z-IETD-FMK.   Finally evaluating the significance of BAP͵ͳ, it is important to consider that we detected pͶ͵/Ͷͳ CASPͺ association as well as BAP͵ͳ cleavage exclusively in PSͺͻ co-treated cells and silencing of BAP͵ͳ did furthermore rescue the chemosensitizing effect. Therefore, we conclude that BAP͵ͳ binding is a crucial feature for the bioactivity of PSͺͻ. The impact of BAP͵ͳ as a druggable tumor target certainly needs further validation and in line, a systematic analysis of BAP͵ͳ expression in hematological malignancies is missing to date. Though, overexpression of BAP͵ͳ seems to correlate with chemoresistance as shown in fludarabine-resistant mantle cell lymphomaͻͳ as well as proteasome inhibitor-adapted myeloma cells.ͻʹ This altogether motivates a deeper analysis of BAP͵ͳ in hematologic cancers and particularly its role in the regulation of apoptotic signaling. 
4.6 Future Perspectives 
4.6.1 The influence of PS89 on BAP31 complex dynamics In order to predict how PSͺͻ interacted either with the membrane-bound or the cytosolic domain of BAP͵ͳ, the discovery of the PSͺͻ binding site will be a relevant field of future research. This could assist further drug optimization studies to develop PSͺͻ derivatives with improved BAP͵ͳ binding properties. However, the structural biology approach is currently limited by the fact that a crystal structure has only been resolved for the C-terminal cytosolic part of BAP͵ͳ yet.ͻ͵   Thus, a more feasible proceeding seems the examination of protein-protein interactions. The Biological General Repository for Interaction Datasets ȋBioGRIDȌͻͶ currently lists ͹ͻ interactors that have been discovered for BAP͵ͳ. As those interactions are potentially altered through the binding of PSͺͻ, a future study aims to elucidate the composition of BAP͵ͳ binding proteins using immunoprecipitation and mass spectrometry as previously described.ͻͷ This method has the potential to uncover how PSͺͻ influences the BAP͵ͳ complex, if it acts in favor of pro-apoptotic interactions or for instance by displacing anti-apoptotic proteins such as Bcl-ʹ and Bcl-xL. 
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4.6.2 The potential of dually targeting the ER and mitochondria Besides the identification of BAP͵ͳ as a novel target of PSͺͻ, the present study particularly shed light on the capability to provoke pro-apoptotic ER-mitochondrial crosstalk by combinatory pharmaceutical intervention. In this area, we propose versatile chances for future drug development. For example, BH͵ mimetics that specifically modify mitochondrial integrity have been identified as a powerful novel compound class to trigger intrinsic apoptosis and encouraging results were recently shown in an AML phase II study with ABT-ͳͻͻ.ͻ͸ Yet, the combination of ABT-ͳͻͻ with PSͺͻ is currently evaluated in our lab aiming to expand the applicability of PSͺͻ combinations beyond classic cytostatics. Alternative to PDI inhibitors, it is also conceivable that proteasome or HSPͻͲ inhibitors are valuable combination partners to tune a pro-apoptotic ER stress response.ʹ͵ 
4.6.3 Analysis of ER-mitochondrial communication by time-lapse microscopy The kinetics of ER and mitochondrial stress triggers will finally be part of the future agenda. This project is motivated by the successful implementation of a method to monitor apoptotic processes in time-lapse.ͻ͹ As depicted in Figure ͵ʹa, the technique is based on single-cell patterning which allows to observe particular cells over the time period of stimulation. As cells are co-incubated with fluorescent markers, specific events such as ROS, calcium, caspase-ͺ and mitochondrial membrane potential can be tracked in parallel. The data of the time-lapse video can then be fitted to determine the onset of the markers and the number of cells that respond to different stimuli ȋFigure ͵ʹaȌ. In the precise case of PSͺͻ combination treatments, it will be of special interest which apoptotic triggers are primary or secondary in the crosstalk of ER and mitochondria. Moreover, it will be exciting how PSͺͻ alters the kinetics of the fluorescent markers in comparison to the single treatment with cytostatics.   While the method was established with adherent cells, it is currently aimed to optimize the patterning for single-cell studies of leukemia cells ȋperformed by Alexandra Murschhauser, group of Prof. Joachim Ra dler, LMU Munich, GermanyȌ. One approach is the immobilization of Jurkat cells by antibody patterning. Yet, single-seeded Jurkat cells could be analyzed after ʹͶ h incubation with stimulants, the redox-sensitive dye CellROX 
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and	propidium	iodide	(Figure	32b).	These	initial	studies	collectively	reveal	the	potential	of	this	method	which	is	not	less	than	the	design	of	rational	drug	combinations	through	an	improved	understanding	of	cellular	communication.		a                 b        Figure 32│Time-lapse microscopy of single-cell fluorescent markers. (a) Protein-coated microarrays are generated following plasma-induced patterning of µ-slides. Adherent cells distribute on the patterned sites after seeding. They are then exposed to apoptotic stimuli and monitored for activation of fluorescent markers using a fluorescence microscope. An automated image processing enables high-throughput analysis of the kinetics of single-cell fluorescence. Scheme adapted from Röttgermann et al.97 (b) Preliminary data for Jurkat single-cell analysis. Microarrays were coated with a CD55 IgM antibody prior to seeding of Jurkat cells (8.000 cells/well). Cells were incubated with 25 µM PS89, 250 nM etoposide, 100 nM CellROX and 0.01 mg/ml propidium iodide. Images were taken after 24 h treatment.   		
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5 Side Project: Vioprolide A 5.1 Introduction Vioprolides	 are	 a	 family	 of	 natural	 compounds	 which	 were	 isolated	 from	 the	myxobacterium	Cystobacter	violaceus	and	first	published	in	1996.98	The	cyclic	structure	of	the	compounds	is	composed	of	eight	amino	acids	plus	one	glyceric	acid	and	is	shown	for	Vioprolide	A	(VioA)	and	Vioprolide	D	(VioD)	in	Figure	33.	For	all	studies,	Vioprolide	stocks	were	provided	by	Prof.	Rolf	Müller	(Saarland	University,	Saarbrücken,	Germany).	                            a         b      Figure 33 │Chemical structure of Vioprolides. (a) Vioprolide A and (b) Vioprolide D. The structural differences are highlighted. The	 initial	 publication	 indicated	 a	 cytotoxic	 activity	 of	 Vioprolides,	 though	 a	 deeper	biological	 evaluation	 has	 been	 missing	 since	 then.	 Within	 the	 DFG	 research	 group	FOR	1406,	the	Vioprolide	project	was	resumed	and	aimed	to	characterize	the	functional	effects	on	cancer	cells	as	well	as	the	mechanisms	behind.	Therefore,	the	transcriptomic	regulation	in	Vioprolide	treated	cells	was	assessed	using	the	sequencing	approach	MACE	(Massive	Analysis	of	cDNA	Ends).		5.2 Anticancer effects of Vioprolide A The	treatment	of	Jurkat	cells	with	low	nanomolar	concentrations	of	VioA	showed	a	dose-dependent	 inhibition	 of	 proliferation	 which	 was	 analyzed	 after	 72	 h	 (Figure	 34a).	 As	Jurkat	cells	visibly	exhibited	apoptotic	phenotypes	at	concentrations	>5	nM,	induction	of	apoptosis	was	subsequently	quantified	applying	higher	concentrations	which	effectively	escalated	 the	 percentage	 of	 apoptotic	 cells	 (Figure	 34b,	 50	 nM	 VioA:	 75%	 apoptotic	cells).	 Notably,	 peripheral	 blood	 mononuclear	 cells	 (PBMCs)	 of	 healthy	 donors	 were	largely	 unaffected	 by	 VioA	 treatment,	 even	 at	 high	 concentrations	 up	 to	 250	nM	VioA	(Figure	34c).			
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 Figure 34│Antileukemic effects of Vioprolide A. (a) Proliferation of Jurkat cells incubated with Vioprolide A 
(VioA) for 72 h. The number of viable cells was determined by CellTiter-Blue staining and normalized 
towards DMSO control. (b) Apoptosis of Jurkat cells treated with VioA for 24 h. Percentage of 
apoptotic cells was determined by propidium iodide staining and flow cytometry. (c) Peripheral blood 
mononuclear cells (PBMCs) treated with VioA for 24 h. The percentage of apoptotic cells was 
determined by flow cytometry. Aiming to translate VioA mediated anticancer effects to other tumor models, the adherent bladder carcinoma cell line TʹͶ was chosen. Similar to Jurkat cells, VioA inhibited to proliferative capacity of TʹͶ cells ȋFigure ͵ͷaȌ. Though quite contrary to Jurkats, apoptosis was significantly lower in TʹͶ cells at higher VioA concentrations ȋFigure ͵ͷb, ͷͲ nM VioA: ͷ% apoptotic cellsȌ. Finally studying the ability of TʹͶ single cells to grow into colonies, a pre-stimulation of the culture with subtoxic doses of VioA showed a long-term effect and inhibited colony formation ȋFigure ͵ͷcȌ.  
   a              b               c       Figure 35│Anticancer effects of Vioprolide A in T24 bladder carcinoma cells. (a) Proliferation of T24 cells 
(DSMZ, cultured in McCoy’s medium, 10% FCS, Pen/Strep) after 72 h stimulation with Vioprolide A 
(VioA). The number of viable cells was determined by CellTiter-Blue staining and normalized towards 
DMSO control. (b) Apoptosis of Jurkat cells treated with VioA for 24 h. Percentage of apoptotic cells 
was determined by propidium iodide staining and flow cytometry. (c) Clonogenic assay of T24 cells 
pre-stimulated for 24 h with VioA. Cells were detached, compounds removed by washing and cells 
reseeded at low density (1250 cells/ml). Colonies were stained after 7 days of proliferation with crystal 
violet (0.5% w/v in 20% methanol/H2O) and images were taken after several washing steps and removal of excessive dye. For quantification, crystal violet was solubilized (0.1 M sodium citrate in 
50% ethanol/H2O) and absorbance was measured at 550 nm (Tecan Sunrise). The percentage of colony forming units (CFU) was expressed as absorbance values normalized to DMSO control.  
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As metastasis of primary tumor cells to distant organs remains a major challenge in the management of solid cancers, the ability of VioA to inhibit migration of TʹͶ was finally evaluated using xCELLigence impedance measurement ȋRoche DiagnosticsȌ. The method allows real-time monitoring of cells migrating through a ͺ µM porous membrane towards a chemoattractant as representatively shown in Figure ͵͸a. The cell index is proportinal to the number of migrating cells and was inhibited with increasing concentrations of VioA applied at subtoxic doses. The antimigratory effects of VioA were confirmed by the quantitative analysis showing a decreased slope of the curves during the time interval of continous migration ȋFigure ͵͸bȌ. 
     a                         b         Figure 36│Antimigratory effects of Vioprolide A. (a) Representative curves of an xCELLigence real-time 
migration experiment. Equilibrated 16-well CIM plates were loaded with FCS-supplemented medium at 
the bottom part and 40.000 cells/well in McCoy medium without FCS in presence or absence of 
Vioprolide A (VioA) at the upper part. Chemotaxis was monitored at 37°C by impedance measurement. 
(b) Quantification of the linear slope during constant migration with RTCA software (Roche 
Diagnostics). Slope values were normalized to DMSO control.    
5.3 Comparative analysis of Vioprolide A and Vioprolide D The publication introducing Vioprolides in ͳͻͻ͸ indicated a distinct specificity of the family members against fungi, yeast and mammalian cells.ͻͺ Here, a comparative dose-response study of Vioprolides A and D on Jurkat cell apoptosis revealed an ECͷͲ of ʹʹ.Ͳ nM for VioA, while VioD was nearly two log cycles less active ȋFigure ͵͹, ECͷͲ = ͳ.͸͹ µMȌ. This result indicated that the slight structural differences in N-heterocycles as outlined in Figure ͵͵ have a significant impact on the bioactivity of Vioprolides.  
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 Figure 37│Dose-dependent apoptosis induction of Vioprolide derivatives. Apoptosis of Jurkat cells treated with 
Vioprolide A (VioA) or Vioprolide D (VioD) for 24 h. Percentage of apoptotic cells was determined by 
propidium iodide staining and flow cytometry. EC50 values were calculated with GraphPad Prism. 
5.4 Massive analysis of cDNA ends (MACE) transcriptome analysis 
5.4.1 Method description Approaching to elucidate biological pathways affected by the cyclic peptide, a transcriptome analysis of cells stimulated with Vioprolide A was performed. In cooperation with Dr. Iris Bischoff ȋGoethe University, Frankfurt, GermanyȌ, the screening method MACE ȋMassive Analysis of cDNA EndsȌ from GenXPro ȋFrankfurt, GermanyȌ was applied. This features an improved detection of rare and short transcripts without the need of length-based normalization compared to full-length RNA-Seq. The experimental procedure is outlined in Figure ͵ͺa. First, the method required the isolation of RNA from stimulated cells and controls. This was followed by the preparation of the cDNA library which was performed with the MACE Kit from GenXPro. It started with barcode tagging of each sample ȋn=͸Ȍ and reverse transcription, then fragmentation and enrichment of cDNA ends and eventually ligation of adaptors necessary for next-generation sequencing ȋNGSȌ. In the final step, the library was conditioned for sequencing using the MiSeq Kit v͵ ȋIllumina, San Diego, CA, USAȌ allowing deep sequencing with ʹͷ million reads overall or approximately Ͷ million reads per sample. One read means that ͳͷͲ bp of each amplified cDNA fragment was sequenced and finally assigned to one of the samples by their individual barcodes. During library preparation, in process control of oligo size ensured that fragmentation by sonication provided appropriate pieces of cDNA as shown in Figure ͵ͺb ȋaverage size specified: ʹͲͲ bpȌ. Furthermore, the successful ligation of adapter sequences was confirmed by a shift of average fragment size from ʹͳͶ bp to ʹ͹ͷ bp. 
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a           b                        Figure 38│Massive analysis of cDNA ends (MACE). (a) Schematic overview of MACE transcriptome analysis adapted from Afonso-Grunz et al.99 RNA was isolated with the RNeasy Mini Kit (Qiagen, Hilden, Germany) and RNA amount determined using a NanoDrop Spectrophotometer ND-1000 (Peqlab, Erlangen, Germany). 4 µg of RNA was put in to prepare the cDNA library with the MACE Kit according to manufacturer’s instructions (GenXPro, Frankfurt, Germany). Fragmentation was performed with a Bioruptor Plus sonication device from Diagnode (Liege, Belgium), cDNA was purified with SPRI magnetic beads (Agencourt AMPure XP, Beckman Coulter, Brea, CA, USA) and enriched with streptavidin affinity beads (provided by GenXPro). After adaptor ligation, cDNA was released from affinity beads, amplified on a GeneAmp PCR System 9700 (Thermo Fisher, Waltham, MA, USA) and purified again (SPRI beads). NGS was performed on a MiSeq system using the MiSeq v3 Kit (Illumina, San Diego, CA, USA) (b) In-process control of oligo size during library preparation. The size of cDNA fragments was determined on a 2200 TapeStation using High Sensitivity D1000 ScreenTape (Agilent, Santa Clara, CA, USA). Peaks designated ‘Lower’ and ‘Upper’ are ScreenTape reference DNAs and the central peak marks the size of cDNA fragments. 5.4.2 Data processing A total of six samples were analyzed by MACE identifying 31890 different reads overall. 
 Jurkat HD (high-dose): 24 h VioA treatment (c = 50 nM) vs. Jurkat DMSO control  
 Jurkat LD (low-dose): 24 h VioA treatment (c = 7.5 nM) vs. Jurkat DMSO control 
 T24: 24 h VioA treatment (c = 15 nM) vs. T24 DMSO control Note:	VioA	stocks	used	for	MACE	analysis	featured	lower	cytotoxic	activity	than	stocks	used	in	section	5.2	which	demanded	an	adjustment	of	doses	(Jurkat	24	h:	<10%	apoptotic	cells	with	VioA	50	nM)			As the cellular basal level of transcripts varies even without treatment, the results of Jurkat HD and LD including n=2 independent data sets of Jurkat contols were subjected to further analysis. Therefore, the gene list was extracted using Microsoft Excel and the selection criteria outlined in Table 21. All raw data of Jurkat and T24 cells accompany this thesis as described in section 8.2. 
 Strepta- vidin coated beads 
Barcoding sequence 
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Table 21│Selection criteria for MACE data analysis. The criteria were applied to extract significantly 
regulated genes from the transcriptome of Jurkat cells treated for 24 h with Vioprolide A (Jurkat HD).  Applying the criteria of Table ʹͳ, n=͸ͳ͸ regulated genes were finally extracted from the transcriptome of VioA treated Jurkat cells ȋJurkat HDȌ in comparison to DMSO control.  
5.4.3 Gene Ontology and KEGG pathway analysis Evaluating if the identified genes were commonly involved in the regulation of specific biological processes or pathways, the data set was first subjected to Gene Ontology ȋGOȌ analysis͹Ͳ using the RAMONA interface ȋRemotely Accessible Multilevel ONtology AnalysisȌ.ͳͲͲ As shown in Figure ͵ͻ, the biological process most likely affected by VioA was cholesterol biosynthesis with n=ͳͲ regulated against n=ͶͶ background genes which belong to the category Ǯcholesterol biosynthetic processǯ.  
 Figure 39│RAMONA analysis of Gene Ontology (GO) biological processes regulated by Vioprolide A. The Jurkat 
HD data set (n=616 genes) was analyzed with the single-model tool of the RAMONA interface against 
homo sapiens genomic background. Results for Gene Ontology (biological process) are shown. 
GO Biological Process
Category Selection criteria 
Unique mapping Exclusion if sequence is not uniquely assigned to one specific gene ȋe. g. sequence match with two of more transcriptsȌ 
High expression >ͳͲ normalized reads in control or treated cells 
Transcript regulation AȌ Control vs. VioA treated:  For normalized reads >ͳͲ: fold-change >ʹ ȋlogʹfold change >ͳȌ For normalized reads >ʹͲ: fold-change >ͳ.ͷ ȋlogʹfold change >Ͳ.͸Ȍ  BȌ Control vs. Control: 
Exclusion if logʹfold change in ȋCtrl vs. CtrlȌ xʹ > ȋCtrl vs. VioAȌ  CȌ Equal tendency of transcript regulation ȋup or downȌ in VioA high-dose ȋJurkat HDȌ and low-dose ȋJurkat LDȌ treatment 
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The GO analysis indicated a modulation of transcripts involved in cholesterol biosynthesis, though did not distinguish between up- or down-regulation. Therefore, the expression of the cholesterol-related genes was examined in the original gene list of control versus VioA treated Jurkat cells. As a result and with exception of Geranylgeranyl pyrophosphate synthase ȋGGPSͳȌ, n=ͻ out of ͳͲ genes were down-regulated ȋTable ʹʹȌ. These included HMG-CoA reductase ȋHMGCR, Ctrl ʹʹͷ.ͶͶ vs. VioA ͳͲͷ.͸ͳ normalized readsȌ which is the rate-limiting enzyme in cholesterol biosynthesis. Of note, SREBFʹ which encodes the sterol regulatory element-binding protein ʹ ȋSREBP-ʹȌ, was also identified to be down-regulated by VioA. This is of special interest as SREPB-ʹ is a key transcription factor controlling cholesterol homeostasis. SREBP-ʹ responsive genes include HMGCSͳ ȋHMG-CoA synthaseȌ, HMGCR ȋHMG-CoA reductaseȌ and squalene synthase ȋFDFTͳȌ,ͳͲͳ all of which were likewise found at lower transcript levels upon VioA treatment ȋTable ʹʹȌ.  
 Table 22│List of genes involved in the regulation of cholesterol biosynthesis. The list shows original MACE 
data for DMSO control (Ctrl) and Vioprolide A (VioA) treated Jurkat cells (Jurkat HD). The upper part 
lists all genes which were regulated by VioA and involved in ‘cholesterol biosynthetic process’ 
according to the Gene Ontology classification. The bottom line shows data for the transcription factor 
SREBF2. Besides the Gene Ontology classification, RAMONA offers a pathway analysis tool which has its source in the KEGG ȋKyoto Encyclopedia of Genes and GenomesȌ database. Feeding the RAMONA interface once again with the n=͸ͳ͸ VioA regulated genes, the pathways with the highest probability of regulation included the terms ǮRNA transportǯ ȋͳ͹/ͳ͸Ͷ, gene list/backgroundȌ which is ubiquitously discovered, ǮProtein processing in ERǯ ȋͳͶ/ͳ͸͹Ȍ and ǮSteroid biosynthesisǯ ȋͷ/ʹͲȌ.  
Gene Protein Name CtrlJurkatHD
VioA
JurkatHD
log2FoldChange
JurkatHDctrl_vs_VioA
DHCR24 Delta(24)-sterol reductase 20,84 9,40 1,15
FDFT1 Squalene synthase 190,39 101,27 0,91
GGPS1 Geranylgeranyl pyrophosphate synthase 69,15 135,27 -0,97
HMGCR 3-hydroxy-3-methylglutaryl-coenzyme A reductase 225,44 105,61 1,09
HMGCS1 Hydroxymethylglutaryl-CoA synthase 72,94 24,60 1,57
INSIG1 Insulin-induced gene 1 protein 310,69 177,95 0,80
LSS Lanosterol synthase 18,94 9,40 1,01
MSMO1 Methylsterol monooxygenase 1 375,10 149,74 1,32
MVD Diphosphomevalonate decarboxylase 12,31 3,62 1,77
SQLE Squalene monooxygenase 388,36 250,29 0,63
SREBF2 Sterol regulatory element-binding protein 2 16,10 5,79 1,48
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Considering the KEGG steroid biosynthetic pathway together with previous results finally enabled to visualize the different levels of VioA mediated transcript alteration ȋFigure ͶͲȌ. In addition to the five down-regulated genes on the level of ǮSteroid biosynthesisǯ according to KEGG, the genes HMGCSͳ, HMGCR and MVD ȋDiphosphomevalonate decarboxylaseȌ are outlined which are involved in the superordinate pathway ǮTerpenoid backbone biosynthesisǯ. 
 Figure 40│RAMONA analysis of the KEGG pathway ‘Steroid biosynthesis’. The Jurkat HD data set (n=616 
genes) was analyzed with the single-model tool of the RAMONA interface against homo sapiens 
genomic background. Results for altered gene expression in the KEGG pathway ‘Steroid biosynthesis’ 
are shown in blue. In addition, altered genes encoding proteins of the KEGG ‘Terpenoid backbone 
biosynthesis’ pathway are listed.  
FDFTϭ ↓
SQLE ↓
LSS ↓
DHCRϮ4 ↓
MSMOϭ ↓
KEGG Pathway
DHCRϮ4 ↓
HMGCS1 ↓, HMGCR ↓, MVD ↓
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5.5 Future prospects As indicated by MACE, a multilevel down-regulation of genes involved in the cholesterol biosynthetic pathway by VioA treatment suggests a decrease of total cellular cholesterol. This in turn could have a therapeutic implication: as cholesterol levels and HMGCR were shown to be increased in acute leukemia samples exposed to standard chemotherapy, a co-treatment of cytostatics with cholesterol synthesis inhibitors was proposed.ͳͲʹ, ͳͲ͵ Furthermore, cholesterol depletion of free and especially membrane-bound cholesterol was recently shown to inhibit proliferation and oncogenic Ras signaling of hepatocellular carcinoma cells.ͳͲͶ However, if cholesterol levels are indeed reduced upon VioA treatment and to which extend this feature finally accounts for the anti-proliferative and pro-apoptotic action of VioA requires further validation.   Moreover, omics screens generally offer a wide scope of possibilities for data extraction and interpretation which may lead to different conclusions. Further bioinformatics analyses of the MACE data could therefore reveal additional pathways that are affected by VioA treatment and contribute to its mode of action. Subsequently, all screening data require a biological validation meaning the verification of VioA mediated gene regulation first on mRNA level by qPCR and second on protein level by Western blot. Finally, the functional consequences of individual gene or network alterations need to be characterized. For the present approach, this will implicate the determination of cholesterol in different cellular compartments and its effect on oncogenic signaling pathways.   In order to further improve our understanding of VioA dynamics, the next step in the Vioprolide project is the identification of direct VioA targets by activity-based protein profiling ȋABPPȌ. The results of the proteomic screen could then be correlated with the MACE data. Therefore, the RAMONA interface may serve as a valuable tool since it is not limited to single-stage analysis, but features a cooperative model for the interpretation of data on two different levels ȋfor example mRNA and proteinȌ.ͳͲͲ Finally, the combination of direct targets and transcriptomics has the potential to highly enhance the understanding of the compoundǯs polypharmacological profile and to put forward a crucial strategy for drug discovery in the omics era. Besides, the identification of direct 
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target proteins by ABPP and subsequent binding studies could help to comprehend the distinct differences in the activities of Vioprolide derivatives that have been outlined here in the comparative study of VioA and VioD.  Beyond the pharmacological characterization of VioA triggered signaling, future studies will be able to refer to the strong anticancer effects of VioA that were demonstrated here. These include anti-proliferative, pro-apoptotic and anti-migratory features which altogether stress the versatile potential of VioA against hematologic malignancies as well as solid cancers. In conclusion, the present study encourages further in vitro and in vivo testing of these highly active natural compounds. 
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6 Contribution: P8-D6 
6.1 Introduction Topoisomerases are vital for many cellular processes such as DNA replication and transcription as they account for the movement and relaxation of torsional strains in the genetic material. Inhibitors of topoisomerases including etoposide and anthracyclines are front-line cytostatics in the therapy of hematologic and solid cancers. Though, side effects such as secondary malignancies and emerging resistances raise a significant need for novel topo-targeting molecules.ͳ͹ Recently, the chemical optimization of naturally occurring benzo[c]phenanthridinde alkaloids by Christopher Meier ȋgroup of Prof. Bernd Clement, Christian Albrechts University, KielȌ yielded the highly active compound Pͺ-D͸ which equipotently inhibits human topoisomerase I and II activities. In order to further characterize the molecular and functional action of this promising compound, a set of experiments was performed in our lab with Jurkat ALL cells. Here, Pͺ-D͸ showed strong growth-inhibitory and pro-apoptotic effects at low nanomolar concentrations ȋͷͲ nM Pͺ-D͸: ͸ͳ.Ͷ% apoptotic cells after ʹͶ hȌ. Moreover, cells arrested in the Gʹ phase of the cell cycle and the phosphorylation of histone HʹAX indicated double-strand breaks as the main apoptotic trigger of Pͺ-D͸. Additionally, Pͺ-D͸ in combination with the chemosensitizing compound PSͺͻ ȋcharacterized in sections ͳ-ͶȌ demonstrated clearly enhanced growth inhibition and apoptosis induction. These results together with the synthetic protocol of Pͺ-D͸, its druggability properties and an in vivo toxicity study have been recently published in ChemMedChem.ͳͲͷ 
6.2 Original Article: A Dual Topoisomerase Inhibitor of Intense Pro-
Apoptotic and Antileukemic Nature for Cancer Treatment The full article highlighting Pͺ-D͸ is presented on the following pages and listed under the Pubmed ID ʹͺͲͻͻ͹ͺͷ. Supplementary information including detailed method descriptions accompanies the article on the ChemMedChem homepage.   
A Dual Topoisomerase Inhibitor of Intense Pro-Apoptotic
and Antileukemic Nature for Cancer Treatment
Christopher Meier,[a] Tamara N. Steinhauer,[a] Fabian Koczian,[b] Birte Plitzko,[a]
Katharina Jarolim,[c] Ulrich Girreser,[a] Simone Braig,[b] Doris Marko,[c] Angelika M. Vollmar,[b]
and Bernd Clement*[a]
Classic cytotoxic drugs remain indispensable instruments in an-
titumor therapy due to their effectiveness and a more preva-
lent insensitivity toward tumor resistance mechanisms. Herein
we describe the favorable properties of 6-(N,N-dimethyl-2-ami-
noethoxy)-11-(3,4,5-trimethoxyphenyl)pyrido[3,4-c][1,9]phenan-
throline (P8-D6), a powerful inducer of apoptosis caused by an
equipotent inhibition of human topoisomerase I and II activi-
ties. A broad-spectrum effect against human tumor cell lines at
nanomolar concentrations, as well as strong antileukemic ef-
fects, were shown to be superior to those of marketed topoi-
somerase-targeting drugs and dual topoisomerase inhibitors in
clinical trials. The facile four-step synthesis, advantageous
drugability properties, and initial in vivo data encourage the
application of P8-D6 in appropriate animal tumor models and
further drug development.
Members of the human topoisomerase (topo) enzyme family
play crucial roles in many cellular actions involving the move-
ment and relaxation of torsional strains in the genetic material.
Their detailed intra-nuclear functions have been studied exten-
sively and are well described in the literature.[1–5] As these op-
erations are required for vital processes such as DNA replica-
tion, transcription, chromatin assembly, and DNA methylation,
topoisomerases I and II have emerged as fundamental targets
for the chemotherapeutic treatment of malignant tumors.[6–10]
Approved topo-targeting drugs such as camptothecin deriva-
tives, acting as topo I poisons, and primarily epipodophyllotox-
ins and anthracyclines that interfere with topo II are highly ef-
fective front-line cytostatic agents for the treatment of system-
ic cancers and solid tumors.[5, 8] The efficacy and experience in
clinical use on the one hand, but also dose- and/or therapy-
limiting side effects and emerging resistance mechanisms
against these agents on the other, demonstrate a significant
medical need for novel topo-targeting molecules.[1, 5, 6, 11–13]
Much effort has gone into the design of dual topo I/II inhibi-
tors that exhibit high cytotoxicity and high affinity for both
enzyme classes. In this regard, the complete inhibition of top-
oisomerase activity in tumor cells was shown to be extremely
effective in vitro and in vivo in a broad range of tumor
types.[1, 14–20] Consequently, dual topo I/II inhibitors were evalu-
ated in phase I/II clinical trials: pyrazoloacridine (PZA, 1), ben-
zopyridoindole intoplicine (2), phenazine derivatives XR11576
(3) and XR5944 (4), batracylin (5), and the indenoquinolinone
TAS-103 (6) (Figure 1), as well as the etoposide derivative taflu-
poside and the homocamptothecin elomotecan.[1, 14, 21–28] Al-
though preclinical studies were very promising for these deriv-
atives, their effectiveness could not be transferred to the clinic
yet.
Naturally occurring benzo[c]phenanthridine alkaloids offer
a broad variety of pharmacological activities.[29–33] Among
them, the quaternary ammonium salts fagaronine and nitidine
(7) were found to possess moderate dual topo I/II poisoning
activity.[34–36] In the mid-1990s our research groups evaluated
a facile and straightforward synthetic route to 11-substituted
6-aminobenzo[c]phenanthridines.[37] The antitumor activity of
derivatives 8 was observed to be high in vitro and in vivo, but
unfortunately their dissatisfactory physicochemical properties
(solubility: low-micromolar range, logD7.4&5) limited further
development of this compound class (Figure 2).[38,39]
To overcome these disadvantages, we synthesized aza-ana-
logs of benzo[c]phenanthridines (compounds 9–14) by using
various o-methylhetarene carbonitriles, and the core system
was systematically adapted and optimized for both physico-
chemical properties and cytotoxicity (Figure 2).[39–42] Applying
the concept of an aminoalkyl side chain linked to a planar core
system to achieve DNA intercalation as well as anti-topoiso-
merase activity,[18] the pyrido[3,4-c][1,9]phenanthroline P8-D6
(19) was found to be by far the most potent derivative of our
compound library. Compound 19 was accessible via a simple
four-step synthetic protocol commencing with commercially
available starting materials to form the 6-amino-11,12-dihydro
derivative 17 in a two-fold ring closure including one-pot syn-
thesis (Scheme 1).[39]
Dehydrogenation with Pd/C followed by diazotation with
NaNO2 in acidic aqueous medium yielded 18.
[40,43] The final
step gave the O-alkylated derivative P8-D6 (19) via Mitsunobu
reaction in an overall yield of 12% (Scheme 1).[44]
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Cytotoxicity was evaluated by the treatment of 60 human
tumor cell lines from nine different tumor types with P8-D6
(NCI-60 DTP human tumor cell line screening, NCI, Bethesda,
MD, USA). Compound 19 showed outstanding overall activity
(expressed as average 50% growth inhibition (GI50) across all
60 cell lines) of 49 nm, in the range of the natural alkaloid
camptothecin. Its growth-inhibitory effect was 4- to 10-fold
higher than other dual topo I/II inhibitors recently elaborated
in clinical trials (Table 1). Besides the good response observed
for all tumor types, the sensitivity of leukemia cells and non-
small cell lung cancer (NSCLC) cells toward P8-D6 was
noted.[45]
P8-D6 is able to inhibit the catalytic activities of both type I
and II topoisomerases at low micromolar concentrations in vi-
tro (Figure 3A,B). In this connection there is no significant dis-
crimination between topo IIa, which reaches maximum protein
levels in the G2/M phase in human cells, and topo IIb, which is
Figure 1. Dual topoisomerase I/II inhibitors in clinical development.[1,14,21–27]
Figure 2. Natural-product-inspired development of aza-analogs of benzo[c]-
phenanthridines.[37–42] R1=OH, R2=OCH3 : fagaronine; R
1–R2= OCH2O: niti-
dine; R3=variously substituted aryl or alkyl groups; R4=H, OH, NH2, or vari-
ous hydrophilic sidechains.
Scheme 1. Four-step synthesis of P8-D6 (19) starting from commercially
available building blocks:[39, 40,43, 44] a) KOtBu, DMPU, 3 h, RT; b) Pd/C, DMPU,
10 min, reflux; c) NaNO2, H3PO2, H2SO4, AcOH, 1 h, 0 8C; d) dimethylaminoe-
thanol, TPP, DIAD, THF, 72 h, RT, HCl(g), CH2Cl2. R
1
=3,4,5-trimethoxyphenyl.
Table 1. Comparison of the cytotoxicity of topoisomerase targeting
agents.
Compound P
GI50
60
[a]
GI50 [mm]
[b]
Leukemia NSCLC Colon cancer
Topoisomerase I inhibitors
CPT[c] 0.04 0.02 0.02 0.08
Irinotecan 0.84 0.20 0.07 1.70
Topotecan 0.04 0.01 0.02 0.09
Topoisomerase II inhibitors
Etoposide 1.32 0.21 0.79 2.51
Teniposide 0.40 0.05 0.27 0.71
Doxorubicin 0.14 0.07 0.07 0.26
Dual topoisomerase I/II inhibitors
P8-D6 0.05 0.02 0.03 0.06
PZA[d] 0.20 0.17 0.17 0.12
Intoplicine 0.53 0.47 0.23 0.50
[a] Mean 50% growth inhibition over all 60 cell lines; data taken from the
DTP-NCI databank, NCI-60 screening data set from September 2014.[45]
[b] Average GI50 values for all comparable cell lines of corresponding
tumor type. [c] Camptothecin. [d] Pyrazoloacridine.
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expressed independently of proliferative status and cell cycle.[1]
A topo-independent DNA attraction, as has been previously re-
ported for structurally related substances, is likewise postulat-
ed.[18,46]
Using flow cytometric analysis of Annexin V-PE and 7-AAD
stained HeLa cells as well as the detection of caspase-mediated
PARP cleavage, it could be demonstrated that P8-D6 is
a strong and rapid inductor of apoptosis (Figure 3C–G).[47,48]
Low-micromolar concentrations of P8-D6 showed pro-apoptot-
ic effects after incubation for 8 h, whereas no PARP cleavage
was observed for etoposide (ETO) or the dual topo inhibitor
PZA before reaching a concentration of 100 mm (Figure 3D,E).
After 24 h incubation, 100- to 1000-fold lower amounts of P8-
D6 were sufficient to induce apoptosis in cells, relative to culti-
vation in the presence of ETO or PZA (Figure 3D,E). PZA treat-
ment also led to partial necrosis of the HeLa cells at these con-
centrations (Figure 3F).
P8-D6 was furthermore tested for antileukemic effects on
Jurkat ALL cells. Making up 30% of all childhood cancers, leu-
kemia is the most common cancer in children, with acute lym-
phoid leukemia (ALL) being most prevalent.[49] The Jurkat ALL
cell line was shown to be sensitive toward P8-D6 treatment, in
Figure 3. P8-D6 is a highly pro-apoptotic dual topoisomerase inhibitor. A) Inhibition of topoisomerase I activity (relaxation assay). B) Inhibition of topoisomer-
ase IIa and IIb (decatenation assay). C) HeLa cells after incubation (24 h) with P8-D6 or etoposide. D),E) PARP apoptosis assay in HeLa cells (ETO/PZA refer-
ence). F) Flow cytometric analysis of pro-apoptotic effects on HeLa cells (after 24 h). G) Quantitative determination of apoptotic cells by flow cytometry (after
24 h). Significant differences relative to DMSO control : ***p,0.001, **p,0.01, *p,0.05.
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accordance with the NCI-60 results. Using proliferation assays,
flow cytometric (FACS) analysis as per protocols reported by
Nicoletti et al. ,[50,51] and western blotting, strong growth-inhibi-
tory and pro-apoptotic effects at low nanomolar concentra-
tions could be confirmed (Figure 4A–C).
Propidium iodide staining and FACS analysis was also used
to evaluate the effects of P8-D6 on the cell cycle. As shown in
Figure 4D, the presence of the substance led to an arrest in
the G2 phase, as expected for a topo inhibitor.
[52] Additionally,
dose-dependent phosphorylation of histone H2A.X (gH2A.X) in
Jurkat ALL cells clearly indicates DNA double-strand breaks as
the main apoptotic trigger of P8-D6 (Figure 4E).[53]
To examine its selectivity for tumor cells, the cytotoxic effect
of P8-D6 was also investigated on healthy human lymphocytes
isolated from whole blood. The results indicate no response of
lymphocytes toward P8-D6 concentrations that are already in-
tensively cytotoxic and pro-apoptotic to the leukemia cell line
(Figure 4F).
Recently, the selective protein disulfide isomerase inhibitor
PS89 was found to sensitize cancer cells toward etoposide
treatment (structure shown in Figure 4G).[54] In this regard, we
analyzed the effects of P8-D6 in combination with the chemo-
sensitizing compound PS89, clearly indicating enhanced
growth inhibition and triggering of apoptosis by sub- or less
toxic P8-D6 concentrations toward Jurkat ALL cells in the pres-
ence of PS89 (Figure 4H,I).
In addition to its pharmacological advantages, P8-D6 exhib-
its a physicochemical profile that encourages its development
as promising drug candidate in antineoplastic chemotherapy.
A solubility of ~1 mm in phosphate buffer (pH 7.4) as well as
accordance with Lipinski’s rule of five parameters for the pre-
diction of oral bioavailability, including a logD7.4 value of 3.7,
would allow even per oral administration (parameters deter-
mined using HPLC analytics).[55]
To evaluate the initial in vivo tolerability of P8-D6, female
athymic nude mice (n=9 vs. nine mice receiving PBS control)
Figure 4. The strong antileukemic effects of P8-D6 and activity toward healthy human lymphocytes. A) Dose-dependent inhibition of Jurkat ALL cell prolifera-
tion by treatment with P8-D6 (Cell TiterBlueS assay, 72 h). B) Dose-dependent induction of apoptosis in Jurkat ALL cells by P8-D6 (Nicoletti assay, 24 h). C) De-
crease of procaspase-3 levels and PARP cleavage in Jurkat ALL cells as hallmarks of apoptosis (P8-D6 treatment, 24 h); actin= loading control. D) Cell-cycle
arrest in the G2 phase by P8-D6 treatment (propidium iodide staining, 24 h). E) Phosphorylation of histone H2A.X as sensitive proof of DNA double-strand
breaks in Jurkat ALL cells (P8-D6 treatment, 24 h). F) No pro-apoptotic effects of P8-D6 on healthy human lymphocytes (FACS analysis, 24 h). G) Structure of
the chemosensitizing protein disulfide isomerase inhibitor PS89. H) Growth inhibition of Jurkat ALL cells by P8-D6 in combination with PS89 (Cell TiterBlueS
assay, 72 h). I) Induction of apoptosis in Jurkat ALL cells by P8-D6 in combination with PS89 (Nicoletti assay, 24 h).
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were treated intravenously (i.v.) with various unique doses of
P8-D6 in PBS. This maximum tolerated dose (MTD) study re-
vealed a good tolerability of 1 mgkg@1 body weight (bw) of
P8-D6 with regard to further in vivo efficacy studies (Figure 5).
In higher concentrations the compound showed dose-depen-
dent toxicity (parameters : body weight, clinical signs), while
loss of body weight and apathy of study animals in the
5 mgkg@1 group were reversible over the period of the study
(Figure 5).
Contrary to macroscopic alterations that had been reported
for mice administered etoposide at low and high doses i.v. in
similar studies,[56] no significant changes in organs were ob-
served for study animals that received i.v. injections of P8-D6
up to 5 mgkg@1 bw (necropsy findings).
Because tumor cells require an enormous amount of cell
components involved in DNA-related growth and replication,
members of the human topoisomerase family are pivotal tar-
gets in antitumor therapy. In summary, our drug candidate P8-
D6 exhibits a number of advantages. The strong and equipo-
tent inhibition of topo I, IIa, and IIb by a dual topoisomerase
inhibitor with an unprecedented excellent cytotoxicity, rapid
and effective tumor-cell-specific pro-apoptotic and antileuke-
mic activity, as well as facile synthetic access in combination
with favorable physicochemical properties, underscore the im-
portance of further in vivo evaluations of P8-D6 in adequate
animal tumor models. Given the improved hydrophilicity of P8-
D6, it is not necessary to provide solubilizing agents for i.v./i.m.
or intraperitoneal (i.p.) injections or infusions, as this was previ-
ously demonstrated in an in vivo tolerability study, which also
provided some initial i.v. dosage information.
The studies described herein clearly highlight P8-D6 as
being much better than the clinically evaluated dual topo in-
hibitor PZA regarding apoptosis-inducing effects. Therefore,
this can be considered a substantial enrichment in the devel-
opment of novel agents that target both topoisomerase I and
II, raising hope for clinical efficacy, in contrast to previously de-
veloped drug candidates of this class. Besides the administra-
tion of P8-D6 alone or in combination with other cytostatic
agents or chemosensitizing compounds, P8-D6 could be an ex-
cellent component in antibody–drug conjugates (ADCs) or
other related modern techniques, most likely applicable
against a broad variety of tumor types.[57]
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8 Appendix 
8.1 Abbreviations ΔΨm Mitochondrial membrane potential ABPP Activity-based protein profiling ALL Acute lymphoblastic leukemia AML Acute myeloid leukemia AMLͳ = RUNXͳ Runt-related transcription factor ͳ Ara-C Cytosine arabinoside, Cytarabine BAP͵ͳ B-cell receptor-associated protein ͵ͳ BCA Bicinchoninic acid bp Base pair BSA Bovine serum albumin BSS Balanced salt solution CASP͵ Caspase-͵ CASPͺ Caspase-ͺ CFU Colony forming unit CHOP C/EBP-homologous protein CTB CellTiter Blue Ctrl Control Cyt c Cytochrome c DHCRʹͶ DeltaȋʹͶȌ-sterol reductase DMSO Dimethyl sulfoxide DNA Deoxyribonucleic acid DNR Daunorubicin ECͷͲ Half maximal effective concentration ECL Enhanced Chemiluminescence Em Emission ER Endoplasmic reticulum ETO Etoposide Ex Excitation FACS Fluorescence activated cell sorting FDFTͳ Squalene synthase FLT͵ Receptor-type tyrosine-protein kinase FLT͵ 
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GGPSͳ Geranylgeranyl pyrophosphate synthase GO Gene Ontology HMGCR ͵-hydroxy-͵-methylglutaryl-coenzyme A reductase HMGCSͳ Hydroxymethylglutaryl-CoA synthase ICͷͲ Half maximal inhibitory concentration INSIGͳ Insulin-induced gene ͳ protein i. p. Intraperitoneal IREͳα Inositol-requiring enzyme ͳ KEGG Kyoto Encyclopedia of Genes and Genomes LSS Lanosterol synthase MACE Massive analysis of cDNA ends MC Methylcellulose MOMP Mitochondrial outer membrane permeabilization MPTP Mitochondrial permeability transition pore mRNA Messenger ribonucleic acid MSMOͳ Methylsterol monooxygenase ͳ MVD Diphosphomevalonate decarboxylase NGS Next-generation sequencing NOTCHͳ Neurogenic locus notch homolog protein ͳ NPMͳ Nucleophosmin NSG NOD ȋNon-obese diabeticȌ scid gamma PARP Poly ADP ribose polymerase PBMC Peripheral blood mononuclear cell PBS Phosphate buffered saline PDI Protein disulfide isomerase PDX Patient derived xenograft PE Phycoerythrin PERK Protein kinase R ȋPKRȌ-like endoplasmic reticulum kinase PI Propidium iodide qPCR Quantitative polymerase chain reaction RAMONA Remotely Accessible Multilevel ONtology Analysis ROS Reactive oxygen species RT Room temperature SCID Severe combined immunodeficiency 
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SEM Standard error of the mean SQLE Squalene monooxygenase SREBFʹ Sterol regulatory element binding transcription factor ʹ STRING Search Tool for the Retrieval of Interacting Genes/Proteins TEL = ETV͸ Transcription factor ETV͸ UPR Unfolded protein response VCR Vincristine VCR-R Vincristine resistant VDAC Voltage-dependent anion channel VioA Vioprolide A VioD Vioprolide D  
8.2 Raw Data: ABPP Proteomics and MACE Transcriptomics Raw data of ABPP and MACE screenings accompany this dissertation on the appended CD-ROM and the electronic thesis website of the LMU Munich:  https://edoc.ub.uni-muenchen.de                 
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meinen Bachelor- und Masterstudenten geleistet. Daher vielen Dank an Britta Hettich, Patrick Spanner und Michaela Koburg fu r Eure Motivation und gute Mitarbeit.  Schließlich soll ein Ho hepunkt der Promotion nicht unerwa hnt bleiben, na mlich die Vorstellung des PSͺͻ Projektes am ͷͺth ASH Annual Meeting. Da dies ohne finanzielle Unterstu tzung nicht mo glich gewesen wa re, geht diesbezu glich mein Dank an Prof. Dr. Angelika Vollmar, die Mu nchner Universita tsgesellschaft sowie die American Society of Hematology.  Dem gesamten AK Vollmar gilt an dieser Stelle noch ein ganz großes Dankescho n fu r den guten Austausch und Umgang miteinander, der Grundlage fu r die ausgesprochen gute Atmospha re im Labor war. Insbesondere Christina, Karin, Meli, Flo und Max - ihr habt die Tage in der Uni, und auch daru ber hinaus, immer mit Leben gefu llt und ich bin sehr glu cklich zusammen mit Euch die letzten Jahre erlebt zu haben.  Zu guter Letzt mo chte ich mich fu r den immer wa hrenden Ru ckhalt meiner Freunde und Familie bedanken. Insbesondere meinen Eltern Andrea und Roland, ich scha tze es wirklich sehr, dass Ihr mir stets die Freiheit gegeben habt meinen Weg zu gehen und diesen uneingeschra nkt gefo rdert habt. 
